Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit
|
摘要
This review analyzes progress and limitations of diagnosis, screening, and therapy of patients with chronic hepatitis B infection. A literature review was carried out by framing the study questions. Vaccination in early childhood has been introduced in most countries and reduces the infection rate. Treatment of chronic hepatitis B can control viral replication in most patients today. It reduces risks for progression and may reverse liver fibrosis. The treatment effect on development of hepatocellular carcinoma is less pronounced when cirrhosis is already present. Despite the success of vaccination and therapy chronic hepatitis B remains a problem since many infected patients do not know of their disease. Although all guidelines recommend screening in high risk groups such as migrants, these suggestions have not been implemented. In addition, the performance of hepatocellular cancer surveillance under real-life conditions is poor. The majority of people with chronic hepatitis B live in resource-constrained settings where effective drugs are not available. Despite the success of vaccination and therapy chronic hepatitis B infection remains a major problem since many patients do not know of their disease. The problems in diagnosis andscreening may be overcome by raising awareness, promoting partnerships, and mobilizing resources.
This review analyzes progress and limitations of diagnosis, screening, and therapy of patients with chronic hepatitis B infection. A literature review was carried out by framing the study questions. Vaccination in early childhood has been introduced in most countries and reduces the infection rate. Treatment of chronic hepatitis B can control viral replication in most patients today. It reduces risks for progression and may reverse liver fibrosis. The treatment effect on development of hepatocellular carcinoma is less pronounced when cirrhosis is already present. Despite the success of vaccination and therapy chronic hepatitis B remains a problem since many infected patients do not know of their disease. Although all guidelines recommend screening in high risk groups such as migrants, these suggestions have not been implemented. In addition, the performance of hepatocellular cancer surveillance under real-life conditions is poor. The majority of people with chronic hepatitis B live in resource-constrained settings where effective drugs are not available. Despite the success of vaccination and therapy chronic hepatitis B infection remains a major problem since many patients do not know of their disease. The problems in diagnosis andscreening may be overcome by raising awareness, promoting partnerships, and mobilizing resources.
This review analyzes progress and limitations of diagnosis, screening, and therapy of patients with chronic hepatitis B infection. A literature review was carried out by framing the study questions. Vaccination in early childhood has been introduced in most countries and reduces the infection rate. Treatment of chronic hepatitis B can control viral replication in most patients today. It reduces risks for progression and may reverse liver fibrosis. The treatment effect on development of hepatocellular carcinoma is less pronounced when cirrhosis is already present. Despite the success of vaccination and therapy chronic hepatitis B remains a problem since many infected patients do not know of their disease. Although all guidelines recommend screening in high risk groups such as migrants, these suggestions have not been implemented. In addition, the performance of hepatocellular cancer surveillance under real-life conditions is poor. The majority of people with chronic hepatitis B live in resource-constrained settings where effective drugs are not available. Despite the success of vaccination and therapy chronic hepatitis B infection remains a major problem since many patients do not know of their disease. The problems in diagnosis andscreening may be overcome by raising awareness, promoting partnerships, and mobilizing resources.
引文
1 World Health Organization.Global alert and response:hepatitis B.Available from:URL:http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index8.html
2 Blachier M,Leleu H,Peck-Radosavljevic M,Valla DC,Roudot-Thoraval F.The burden of liver disease in Europe.EASL2013.Available from:URL:http://www.easl.eu/assets/.../54 ae845caec619f_file.pdf
3 European Associations for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection.J Hepatol 2012;57:167-185[PMID:22436845]
4 Liaw YF,Kao JH,Piratvuth T,Chan HLY,Chien RN,Liu CJ.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update.Hepatol Int 2012;6:531-561[DOI 10.1007/s12072-012-9365-9364]
5 Lok AS,McMahon BJ.Chronic hepatitis B:update 2009.Hepatology 2009;50:661-662[PMID:19714720 DOI:10.1002/hep.23190]
6 Marcellin P,Gane E,Buti M,Afdhal N,Sievert W,Jacobson IM,Washington MK,Germanidis G,Flaherty JF,Schall RA,Bornstein JD,Kitrinos KM,Subramanian GM,McHutchison JG,Heathcote EJ.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a5 -year open-label follow-up study.Lancet 2013;381:468-475[PMID:23234725 DOI:10.1016/S0140-6736(12)61425-1]
7 Chang TT,Liaw YF,Wu SS,Schiff E,Han KH,Lai CL,Safadi R,Lee SS,Halota W,Goodman Z,Chi YC,Zhang H,Hindes R,Iloeje U,Beebe S,Kreter B.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.Hepatology 2010;52:886-893[PMID:20683932 DOI:10.1002/hep.23785]
8 Niro GA,Ippolito AM,Fontana R,Valvano MR,Gioffreda D,Iacobellis A,Merla A,Durazzo M,Lotti G,Di Mauro L,Andriulli A.Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.J Viral Hepat 2013;20:502-509[PMID:23730844 DOI:10 .1111/jvh.12054]
9 Kim CH,Um SH,Seo YS,Jung JY,Kim JD,Yim HJ,Keum B,Kim YS,Jeen YT,Lee HS,Chun HJ,Kim CD,Ryu HS.Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.J Gastroenterol Hepatol 2012;27:1589-1595[PMID:22554121 DOI:10.1111/j.1440-1746.2012.07167.x]
10 Papatheodoridis GV,Manolakopoulos S,Touloumi G,Vourli G,Raptopoulou-Gigi M,Vafiadis-Zoumbouli I,Vasiliadis T,Mimidis K,Gogos C,Ketikoglou I,Manesis EK.Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s)starting with lamivudine monotherapy:results of the nationwide HEPNET.Greece cohort study.Gut 2011;60:1109-1116[PMID:21270118 DOI:10.1136/gut.2010.221846]
11 Jin YJ,Shim JH,Lee HC,Yoo DJ,Kim KM,Lim YS,Suh DJ.Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.J Gastroenterol Hepatol 2011;26:1380-1388[PMID:21884247 DOI:10.1111/j.1440-1746.2011.06776.x]
12 Hosaka T,Suzuki F,Kobayashi M,Seko Y,Kawamura Y,Sezaki H,Akuta N,Suzuki Y,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Kumada H.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.Hepatology 2013;58:98-107[PMID:23213040 DOI:10.1002/hep.26180]
13 Zoutendijk R,Reijnders JG,Zoulim F,Brown A,Mutimer DJ,Deterding K,Hofmann WP,Petersen J,Fasano M,Buti M,Berg T,Hansen BE,Sonneveld MJ,Wedemeyer H,Janssen HL.Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.Gut 2013;62:760-765[PMID:22490523 DOI:10 .1136/gutjnl-2012-302024]
14 Singal AK,Salameh H,Kuo YF,Fontana RJ.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.Aliment Pharmacol Ther 2013;38:98-106[PMID:23713520 DOI:10.1111/apt.12344]
15 Cadranel JF,Lahmek P,Causse X,Bellaiche G,Bettan L,Fontanges T,Medini A,Henrion J,Chousterman M,Condat B,Hervio P,Periac P,Eugène C,Moindrot H,Grasset D,Nouel O,Pilette C,Szostak-Talbodec N,Cayla JM,Si-Ahmed SN,Dumouchel P,Pariente A,Lesgourgues B,Denis J.Epidemiology of chronic hepatitis B infection in France:risk factors for significant fibrosis--results of a nationwide survey.Aliment Pharmacol Ther 2007;26:565-576[PMID:17661760]
16 Mota A,Areias J,Cardoso MF.Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in northern Portugal with reference to the viral genotypes.J Med Virol 2011;83:71-77[PMID:21108341 DOI:10.1002/jmv.21939]
17 Larsen JJ.alpha And beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man.Br J Pharmacol 1979;65:215-222[PMID:216452 DOI:10.1111/j.14783231.2010.02373.x]
18 Almasio PL,CraxìA.Management of hepatitis B virus infection in the underprivileged world.Liver Int 2011;31:749-750[PMID:21645204 DOI:10.1111/j.1478-3231.2011.02477.x]
19 European Liver Patients Association.Report on hepatitis patient self-help in Europe;2010.Available from:URL:http://www.hepbcppa.org/wp-content/uploads/2011/11/Report-on-Patient-Self-Help.pdf
20 Piorkowsky NY.Europe’s hepatitis challenge:defusing the“viral time bomb”.J Hepatol 2009;51:1068-1073[PMID:19854528 DOI:10.1016/j.jhep.2009.09.010]
21 McPherson S,Valappil M,Moses SE,Eltringham G,Miller C,Baxter K,Chan A,Shafiq K,Saeed A,Qureshi R,Hudson M,Bassendine MF.Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England.J Viral Hepat2013;20:638-644[PMID:23910648 DOI:10.1111/jvh.12084]
22 Cohen C,Holmberg SD,McMahon BJ,Block JM,Brosgart CL,Gish RG,London WT,Block TM.Is chronic hepatitis B being undertreated in the United StatesJ Viral Hepat 2011;18:377-383[PMID:21143343 DOI:10.1111/j.13652893.2010.01401.x]
23 Richter C,Beest GT,Sancak I,Aydinly R,Bulbul K,Laetemia-Tomata F,De Leeuw M,Waegemaekers T,Swanink C,Roovers E.Hepatitis B prevalence in the Turkish population of Arnhem:implications for national screening policyEpidemiol Infect 2012;140:724-730[PMID:21740610 DOI:10.1017/S0950268811001270]
24 Meffre C,Le Strat Y,Delarocque-Astagneau E,Dubois F,Antona D,Lemasson JM,Warszawski J,Steinmetz J,Coste D,Meyer JF,Leiser S,Giordanella JP,Gueguen R,Desenclos JC.Prevalence of hepatitis B and hepatitis C virus infections in France in 2004:social factors are important predictors after adjusting for known risk factors.J Med Virol 2010;82:546-555[PMID:20166185 DOI:10.1002/jmv.21734]
25 HahnéSJ,De Melker HE,Kretzschmar M,Mollema L,Van Der Klis FR,Van Der Sande MA,Boot HJ.Prevalence of hepatitis B virus infection in The Netherlands in 1996 and 2007.Epidemiol Infect 2012;140:1469-1480[PMID:22078095 DOI:10 .1017/S095026881100224X]
26 Lin SY,Chang ET,So SK.Stopping a silent killer in the underserved asian and pacific islander community:a chronic hepatitis B and liver cancer prevention clinic by medical students.Asian Pac J Cancer Prev 2009;10:383-386[PMID:19640178]
27 Rossi C,Shrier I,Marshall L,Cnossen S,Schwartzman K,Klein MB,Schwarzer G,Greenaway C.Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees:a systematic review and metaanalysis.PLoS One 2012;7:e44611[PMID:22957088 DOI:10 .1371/journal.pone.0044611]
28 Viral Hepatitis Prevention Board.The clock is running.1997:Deadline for integrating hepatitis B vaccinations into all national immunization programmes,1996(Fact Sheet VHPB/1996/1.Available from:URL:http://hgins.uia.ac.be/esoc/VHPB/vhfs1.html
29 Ganem D,Prince AM.Hepatitis B virus infection--natural history and clinical consequences.N Engl J Med 2004;350:1118-1129[PMID:15014185]
30 Hoofnagle JH,Doo E,Liang TJ,Fleischer R,Lok AS.Management of hepatitis B:summary of a clinical research workshop.Hepatology 2007;45:1056-1075[PMID:17393513]
31 Liaw YF.Prevention and surveillance of hepatitis B virusrelated hepatocellular carcinoma.Semin Liver Dis 2005;25Suppl 1:40-47[PMID:16103980]
32 Lok AS,McMahon BJ.Chronic hepatitis B.Hepatology 2007;45 :507-539[PMID:17256718]
33 Hollinger FB,Liang TJ.Hepatitis B Virus.In:Knipe DM,editor.Fields Virology.4th ed.Philadelphia:Lippincott Williams Wilkins,2001:2971-3036
34 Mahoney FJ,Kane M.Hepatitis B vaccine.In:Plotkin SA,Orenstein WA,editors.Vaccines.3rd ed.Philadelphia:W.B.Saunders Company,1999:158-182
35 Viral Hepatitis Prevention Board.Universal HB immunization by 1997:where are we now1998(Fact Sheet VHPB/1998/2)Available from:URL:http://hgins.uia.ac.be/esoc/VHPB/vhfs2.html
36 Ott JJ,Stevens GA,Groeger J,Wiersma ST.Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity.Vaccine 2012;30:2212-2219[PMID:22273662 DOI:10.1016/j.vaccine.2011.12.116]
37 Hyams KC.Risks of chronicity following acute hepatitis B virus infection:a review.Clin Infect Dis 1995;20:992-1000[PMID:7795104]
38 Custer B,Sullivan SD,Hazlet TK,Iloeje U,Veenstra DL,Kowdley KV.Global epidemiology of hepatitis B virus.J Clin Gastroenterol 2004;38:S158-S168[PMID:15602165 DOI:10 .1097/00004836-200411003-00008]
39 Redd JT,Baumbach J,Kohn W,Nainan O,Khristova M,Williams I.Patient-to-patient transmission of hepatitis B virus associated with oral surgery.J Infect Dis 2007;195:1311-1314[PMID:17397000 DOI:10.1086/513435]
40 Alter MJ.Epidemiology and prevention of hepatitis B.Semin Liver Dis 2003;23:39-46[PMID:12616449 DOI:10.1055/s2003-37583]
41 Van Damme P.Hepatitis B:vaccination programmes in Europe--an update.Vaccine 2001;19:2375-2379[PMID:11257363]
42 Hatzakis A,Wait S,Bruix J,Buti M,Carballo M,Cavaleri M,Colombo M,Delarocque-Astagneau E,Dusheiko G,Esmat G,Esteban R,Goldberg D,Gore C,Lok AS,Manns M,Marcellin P,Papatheodoridis G,Peterle A,Prati D,Piorkowsky N,Rizzetto M,Roudot-Thoraval F,Soriano V,Thomas HC,Thursz M,Valla D,van Damme P,Veldhuijzen IK,Wedemeyer H,Wiessing L,Zanetti AR,Janssen HL.The state of hepatitis B and C in Europe:report from the hepatitis B and C summit conference*.J Viral Hepat 2011;18 Suppl 1:1-16[PMID:21824223 DOI:10.1111/j.1365-2893.2011.01499.x]
43 Duberg AS,Trner A,Davidsdóttir L,Aleman S,Blaxhult A,Svensson A,Hultcrantz R,Bck E,Ekdahl K.Cause of death in individuals with chronic HBV and/or HCV infection,a nationwide community-based register study.J Viral Hepat 2008;15:538-550[PMID:18397223 DOI:10.1111/j.1365-2893.2008.00982.x]
44 García-Fulgueiras A,García-Pina R,Morant C,GarcíaOrtuzar V,Génova R,Alvarez E.Hepatitis C and hepatitis B-related mortality in Spain.Eur J Gastroenterol Hepatol 2009;21:895-901[PMID:19357523 DOI:10.1097/MEG.0b013e328313139d]
45 Marcellin P,Pequignot F,Delarocque-Astagneau E,Zarski JP,Ganne N,Hillon P,Antona D,Bovet M,Mechain M,Asselah T,Desenclos JC,Jougla E.Mortality related to chronic hepatitis B and chronic hepatitis C in France:evidence for the role of HIV coinfection and alcohol consumption.J Hepatol 2008;48:200-207[PMID:18086507]
46 Salleras L,Domínguez A,Bruguera M,Plans P,Espues J,Costa J,Cardeosa N,Plasència A.Seroepidemiology of hepatitis B virus infection in pregnant women in Catalonia(Spain).J Clin Virol 2009;44:329-332[PMID:19230752 DOI:10 .1016/j.jcv.2009.01.002]
47 Zacharakis G,Kotsiou S,Papoutselis M,Vafiadis N,Tzara F,Pouliou E,Maltezos E,Koskinas J,Papoutselis K.Changes in the epidemiology of hepatitis B virus infection following the implementation of immunisation programmes in northeastern Greece.Euro Surveill 2009;14:[PMID:19679032]
48 Fattovich G.Natural history and prognosis of hepatitis B.Semin Liver Dis 2003;23:47-58[PMID:12616450]
49 McMahon BJ.Epidemiology and natural history of hepatitis B.Semin Liver Dis 2005;25 Suppl 1:3-8[PMID:16103976]
50 Hadziyannis SJ,Papatheodoridis GV.Hepatitis B e antigennegative chronic hepatitis B:natural history and treatment.Semin Liver Dis 2006;26:130-141[PMID:16673291]
51 Zarski JP,Marcellin P,Leroy V,Trepo C,Samuel D,GanneCarrie N,Barange K,Canva V,Doffoel M,Cales P.Characteristics of patients with chronic hepatitis B in France:predominant frequency of HBe antigen negative cases.J Hepatol2006;45:355-360[PMID:16750585]
52 Funk ML,Rosenberg DM,Lok AS.World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.J Viral Hepat 2002;9:52 -61[PMID:11851903]
53 Liaw YF,Tai DI,Chu CM,Chen TJ.The development of cirrhosis in patients with chronic type B hepatitis:a prospective study.Hepatology 1998;8:493-496[PMID:3371868]
54 Lin SM,Yu ML,Lee CM,Chien RN,Sheen IS,Chu CM,Liaw YF.Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.J Hepatol 2007;46:45-52[PMID:17107734]
55 Park BK,Park YN,Ahn SH,Lee KS,Chon CY,Moon YM,Park C,Han KH.Long-term outcome of chronic hepatitis B based on histological grade and stage.J Gastroenterol Hepatol2007;22:383-388[PMID:17295771]
56 Wu CF,Yu MW,Lin CL,Liu CJ,Shih WL,Tsai KS,Chen CJ.Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men.Carcinogenesis 2008;29:106-112[PMID:17999990]
57 Chen CF,Lee WC,Yang HI,Chang HC,Jen CL,Iloeje UH,Su J,Hsiao CK,Wang LY,You SL,Lu SN,Chen CJ.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.Gastroenterology2011;141:1240-128,1240-128,[PMID:21703214 DOI:10.1053/j.gastro.2011]
58 Yang HI,Lu SN,Liaw YF,You SL,Sun CA,Wang LY,Hsiao CK,Chen PJ,Chen DS,Chen CJ.Hepatitis B e antigen and the risk of hepatocellular carcinoma.N Engl J Med 2002;347:168 -174[PMID:12124405]
59 Iloeje UH,Yang HI,Su J,Jen CL,You SL,Chen CJ.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.Gastroenterology 2006;130:678-686[PMID:16530509]
60 Chen CJ,Yang HI,Su J,Jen CL,You SL,Lu SN,Huang GT,Iloeje UH.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA2006;295:65-73[PMID:16391218]
61 Chen CL,Yang HI,Yang WS,Liu CJ,Chen PJ,You SL,Wang LY,Sun CA,Lu SN,Chen DS,Chen CJ.Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:a follow-up study in Taiwan.Gastroenterology 2008;135:111-121[PMID:18505690 DOI:10.1053/j.gastro.2008.03.073]
62 Yu MW,Shih WL,Lin CL,Liu CJ,Jian JW,Tsai KS,Chen CJ.Body-mass index and progression of hepatitis B:a population-based cohort study in men.J Clin Oncol 2008;26:5576-5582[PMID:18955457 DOI:10.1200/JCO.2008.16.1075]
63 Young EW,Koch PB,Preston DB.AIDS and homosexuality:a longitudinal study of knowledge and attitude change among rural nurses.Public Health Nurs 1989;6:189-196[PMID:2616450]
64 Fattovich G,Bortolotti F,Donato F.Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors.J Hepatol 2008;48:335-352[PMID:18096267]
65 Fattovich G,Olivari N,Pasino M,D’Onofrio M,Martone E,Donato F.Long-term outcome of chronic hepatitis B in Caucasian patients:mortality after 25 years.Gut 2008;57:84-90[PMID:17715267]
66 Fattovich G,Stroffolini T,Zagni I,Donato F.Hepatocellular carcinoma in cirrhosis:incidence and risk factors.Gastroenterology 2004;127:S35-S50[PMID:15508101]
67 Chen YC,Chu CM,Yeh CT,Liaw YF.Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a long-term follow-up study.Hepatol Int 2007;1:267-273[PMID:19669348]
68 Chu CM,Liaw YF.Hepatitis B virus-related cirrhosis:natural history and treatment.Semin Liver Dis 2006;26:142-152[PMID:16673292]
69 Kappus MR,Sterling RK.Extrahepatic manifestations of acute hepatitis B virus infection.Gastroenterol Hepatol(N Y)2013;9:123-126[PMID:23983659]
70 World Health Organization position paper.Hepatitis B vaccines:Weekly epidemiological record:2009;40:405-420.Available from:URL:http://www.who.int/wer
71 AndréFE.Summary of safety and efficacy data on a yeastderived hepatitis B vaccine.Am J Med 1989;87:14S-20S[PMID:2528292]
72 McMahon BJ,Helminiak C,Wainwright RB,Bulkow L,Trimble BA,Wainwright K.Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons.Am J Med 1992;92:254 -256[PMID:1532114]
73 Update:vaccine side effects,adverse reactions,contraindications,and precautions.Recommendations of the Advisory Committee on Immunization Practices(ACIP)MMWR Recomm Rep 1996;45:1-35[PMID:8801442]
74 Chang MH,Chen CJ,Lai MS,Hsu HM,Wu TC,Kong MS,Liang DC,Shau WY,Chen DS.Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.Taiwan Childhood Hepatoma Study Group.N Engl J Med 1997;336:1855-1859[PMID:9197213]
75 World Health Organization.Available from:URL:http://www.who.int/immunization/hepb_grad_24hours.pdf
76 McMahon BJ,Bulkow LR,Singleton RJ,Williams J,Snowball M,Homan C,Parkinson AJ.Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program.Hepatology 2011;54:801-807[PMID:21618565 DOI:10.1002/hep.24442]
77 Wong VW,Chan HL.Prevention of hepatocellular carcinoma:a concise review of contemporary issues.Ann Hepatol2012;11:284-293[PMID:22481445]
78 Chen DS,Locarnini S,Wait S,Bae SH,Chen PJ,Fung JY,Kim HS,Lu SN,Sung J,Tanaka J,Wakita T,Ward J,Wallace J;CEVHAP North Asia Workshop on Viral Hepatitis.CEVHAP North Asia Workshop on Viral Hepatitis.Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia.J Hepatol 2013;59:1073-1080[PMID:23850942 DOI:10 .1016/j.jhep.2013.06.029]
79 Lee MS,Kim DH,Kim H,Lee HS,Kim CY,Park TS,Yoo KY,Park BJ,Ahn YO.Hepatitis B vaccination and reduced risk of primary liver cancer among male adults:a cohort study in Korea.Int J Epidemiol 1998;27:316-319[PMID:9602416]
80 Blumberg BS.Primary and secondary prevention of liver cancer caused by HBV.Front Biosci(Schol Ed)2010;2:756 -763[PMID:20036981]
81 Quoilin S,Hutse V,Vandenberghe H,Claeys F,Verhaegen E,De Cock L,Van Loock F,Top G,Van Damme P,Vranckx R,Van Oyen H.A population-based prevalence study of hepatitis A,B and C virus using oral fluid in Flanders,Belgium.Eur J Epidemiol 2007;22:195-202[PMID:17356926]
82 Nardone A,Anastassopoulou CG,Theeten H,Kriz B,Davidkin I,Thierfelder W,O’Flanagan D,Bruzzone B,Mossong J,Boot HJ,Butur D,SlacikováM,Panait ML,Hellenbrand W,DE Melker H,SobotováZ,Icardi G,Andrews N,Pebody RG,VAN Damme P,Kafatos G,Miller E,Hatzakis A.A comparison of hepatitis B seroepidemiology in ten European countries.Epidemiol Infect 2009;137:961-969[PMID:19102797DOI:10.1017/S0950268808001672]
83 Czarkowski MP,Bobel D.[Hepatitis B in Poland in 2006].Przegl Epidemiol 2008;62:317-324[PMID:18807474]
84 Czarkowski MP,Rosińska M.[Hepatitis B in Poland in2005].Przegl Epidemiol 2007;61:273-279[PMID:17956042]
85 Pitigoi D,Rafila A,Pistol A,Arama V,Molagic V,StreinuCercel A.Trends in hepatitis B incidence in Romania,1989-2005.Euro Surveill 2008;13:[PMID:18445385]
86 Papaevangelou V,Hadjichristodoulou C,Cassimos DC,Pantelaki K,Tzivaras A,Hatzimichael A,Theodoridou M.Seroepidemiology of hepatitis B in Greek children 6years after the implementation of universal vaccination.Infection 2008;36:135-139[PMID:18231718 DOI:10.1007/s15010-007-7096-6]
87 Fabris P,Baldo V,Baldovin T,Bellotto E,Rassu M,Trivello R,Tramarin A,Tositti G,Floreani A.Changing epidemiology of HCV and HBV infections in Northern Italy:a survey in the general population.J Clin Gastroenterol 2008;42:527-532[PMID:18277889 DOI:10.1097/MCG.0b013e318030e3ab]
88 Baaten GG,Sonder GJ,Dukers NH,Coutinho RA,Van den Hoek JA.Population-based study on the seroprevalence of hepatitis A,B,and C virus infection in Amsterdam,2004.J Med Virol 2007;79:1802-1810[PMID:17935187]
89 Voiculescu M,Iliescu L,Ionescu C,Micu L,Ismail G,Zilisteanu D,Radasan A,Micu G,Pertache I.A cross-sectional epidemiological study of HBV,HCV,HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania.J Gastrointestin Liver Dis 2010;19:43-48[PMID:20361074]
90 Salleras L,Domínguez A,Bruguera M,Plans P,Costa J,Cardeosa N,Batalla J,Plasència A.Declining prevalence of hepatitis B virus infection in Catalonia(Spain)12 years after the introduction of universal vaccination.Vaccine 2007;25:8726-8731[PMID:18045753]
91 Sorrell MF,Belongia EA,Costa J,Gareen IF,Grem JL,Inadomi JM,Kern ER,McHugh JA,Petersen GM,Rein MF,Strader DB,Trotter HT.National Institutes of Health Consensus Development Conference Statement:management of hepatitis B.Ann Intern Med 2009;150:104-110[PMID:19124811]
92 Weinbaum CM,Williams I,Mast EE,Wang SA,Finelli L,Wasley A,Neitzel SM,Ward JW.Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.MMWR Recomm Rep 2008;57 :1-20[PMID:18802412]
93 Gastroenterological Society of Australia and Digestive Health Foundation.Australian and New Zealand chronic hepatitis B(CHB)recommendations.Clinical update[webpage on the Internet].Victoria,Australia:The Digestive Health Foundation;2010.Available from:URL:http://www.gesa.org.au/files/editor_upload/File/Professional/CHB.pdf
94 Kowdley KV,Wang CC,Welch S,Roberts H,Brosgart CL.Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin.Hepatology 2012;56:422-433[PMID:22105832 DOI:10.1002/hep.24804]
95 Wilson JM,Jungner G.Principles and practice of screening for disease.Geneva,Switzerland:World Health Organization,1968
96 Almy TP.Our“amber waves of grain”.Hosp Pract 1976;11:11 ,16[PMID:1017829]
97 Hutton DW,Tan D,So SK,Brandeau ML.Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.Ann Intern Med 2007;147:460-469[PMID:17909207]
98 Veldhuijzen IK,Toy M,HahnéSJ,De Wit GA,Schalm SW,de Man RA,Richardus JH.Screening and early treatment of migrants for chronic hepatitis B virus infection is costeffective.Gastroenterology 2010;138:522-530[PMID:19879275DOI:10.1053/j.gastro.2009.10.039]
99 Rein DB,Lesesne SB,Smith BD,Weinbaum CM.Models of community-based hepatitis B surface antigen screening programs in the U.S.and their estimated outcomes and costs.Public Health Rep 2011;126:560-567[PMID:21800750]
100 Wong WW,Woo G,Jenny Heathcote E,Krahn M.Cost effectiveness of screening immigrants for hepatitis B.Liver Int 2011;31:1179-1190[PMID:21745300 DOI:10.1111/j.1478-3231.2011.02559.x]
101 Canadian Agency for Drugs and Technologies in Health.Common Drug Review Drug Database.Ottawa,ON,Canada:Canadian Agency for Drugs and Technologies in Health,2009.Available from:URL:http://www.cadth.ca/en/products/cde
102 Fischer C,Mauss S,Zehnter E,Bokemeyer B,Heyne R,Hüppe D.[Epidemiology and clinical characteristics of patients with chronic hepatitis B(CHB)in Germany-results of a nationwide cross-sectional study].Z Gastroenterol 2012;50:22 -29[PMID:22222794 DOI:10.1055/s-0031-1281628]
103 Niederau C,Heintges T,Niederau M,Stremmel W,Strohmeyer G.[How many patients with chronic viral hepatitis qualify for interferon therapyProspective analysis of university ambulatory care].Med Klin(Munich)1993;88:511-55,562 [PMID:8232088]
104 Cornberg M,Protzer U,Petersen J,Wedemeyer H,Berg T,Jilg W,Erhardt A,Wirth S,Sarrazin C,Dollinger MM,Schirmacher P,Dathe K,Kopp IB,Zeuzem S,Gerlich WH,Manns MP.[Prophylaxis,diagnosis and therapy of hepatitis B virus infection-the German guideline].Z Gastroenterol 2011;49:871-930[PMID:21748700 DOI:10.1055/s-0031-1273462]
105 Sarrazin C,Berg T,Ross RS,Schirmacher P,Wedemeyer H,Neumann U,Schmidt HH,Spengler U,Wirth S,Kessler HH,Peck-Radosavljevic M,Ferenci P,Vogel W,Moradpour D,Heim M,Cornberg M,Protzer U,Manns MP,Fleig WE,Dollinger MM,Zeuzem S.[Prophylaxis,diagnosis and therapy of hepatitis C virus(HCV)infection:the German guidelines on the management of HCV infection].Z Gastroenterol 2010;48:289 -351[PMID:20119896 DOI:10.1055/s-0028-1110008]
106 Tozun N,Ozdogan OC,Cakaloglu Y,Idilman R,Karasu Z,Akarca US.A Nationwide Prevalence Study and Risk Factors for Hepatitis A,B,C and D Infections in Turkey.Boston:AASLD National Meeting in Boston,2010:A789
107 Contini C,Badia L,Cultrera R,Grilli A,De Togni A.Epidemiological,clinical and laboratory features of chronic hepatitis B infection in a cohort of immigrant and Italian patients from Ferrara,Italy.Ann Hepatol 2012;11:862-869[PMID:23109449]
108 Levi M,Bonanni P,Falla A,Veldhuijzen I.Awareness of hepatitis B and C screening and patients management guidelines among health care professionals in six eurpean countries.Annual Meeting of the European Association for the Study of the Liver,Amsterdam 2013.J Hepatol 2013;58:A2568
109 Falla A,Veldhuijzen I,Ahmad A,Levi M,Richardus JH.Chronic hepatitis B and C management and treatment restrictions-current practice in 6 european countries.Annual Meeting of the European Association for the Study of the Liver,Amsterdam 2013.J Hepatol 2013;58:A2479
110 Vermehren J,Schlosser B,Domke D,Elanjimattom S,Müller C,Hintereder G,Hensel-Wiegel K,Tauber R,Berger A,Haas N,Walcher F,Mckel M,Lehmann R,Zeuzem S,Sarrazin C,Berg T.High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany:a prospective screening analysis of 28,809 patients.PLoS One 2012;7:e41206[PMID:22848445 DOI:10.1371/journal.pone.0041206]
111 Buggisch P,Petersen J,Urlea-Schn I.High prevalence of chronic hepatitis C in 8009 patients with migration background living in Germany.Meeting of the AASLD 2012 in Boston.Hepatology 2012;56:A768
112 Niederau C,Zehnter E,Kapagiannidis C.Werden die Empfehlungen des Robert-Koch-Instituts(RKI)zur Diagnose der Hepatitis C im hausrztlichen Bereich umgesetztEine prospektive Untersuchung von 192 Hausarztpraxen in Deutschland.Z Gastroenterol 2006;44:A320
113 Rossol S,Bartel J.[Chronic hepatitis C virus infection].MMW Fortschr Med 2006;148:36-37[PMID:17619422]
114 Wedemeyer H,Hofmann WP,Lueth S,Malinski P,Thimme R,Tacke F,Wiegand J.[ALT screening for chronic liver diseases:scrutinizing the evidence].Z Gastroenterol 2010;48:46 -55[PMID:20072996 DOI:10.1055/s-00281109980]
115 Kunkel J,Ahmad A,Levi M,Reintjes R,Veldhuijzen,Foster G.Screening for viral hepatitis among migrants in the EUThe quest for“good screening practice”.Annual Meeting of the European Association for the Study of the Liver,Amsterdam 2013.J Hepatol 2013;58:A2281
116 van der Veen YJ,de Zwart O,Voeten HA,Mackenbach JP,Richardus JH.Hepatitis B screening in the Turkish-Dutch population in Rotterdam,the Netherlands;qualitative assessment of socio-cultural determinants.BMC Public Health2009;9:328[PMID:19740421 DOI:10.1186/1471-2458-9-328]
117 Malespin M,Wong S,Siqueira F,Luc B,Ravaee B,Vainder C,Cotler SJ.Barriers to treatment of hepatitis B in an urban Chinatown community.J Clin Gastroenterol 2012;46:e66-e70[PMID:22460162 DOI:10.1097/MCG.0b013e31824e159c]
118 RRobotin M,Patton Y,George J.Getting it right:the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers.Int J Gen Med 2013:6 115-122[PMID:23662074 DOI:10.2147/IJGM.S41299]
119 HahnéSJ,Veldhuijzen IK,Wiessing L,Lim TA,Salminen M,Laar Mv.Infection with hepatitis B and C virus in Europe:a systematic review of prevalence and cost-effectiveness of screening.BMC Infect Dis 2013;13:181[PMID:23597411DOI:10.1186/1471-2334-13-181]
120 Dulay M,Zola J,Hwang J,Baron A,Lai C.Are primary care clinicians knowledgeable about screening for chronic hepatitis B infectionJ Gen Intern Med 2007;22:747-753
121 Lai CJ,Nguyen TT,Hwang J,Stewart SL,Kwan A,McPhee SJ.Provider knowledge and practice regarding hepatitis B screening in Chinese-speaking patients.J Cancer Educ 2007;22 :37-41[PMID:17570807]
122 Tormans G,Van Damme P,Carrin G,Clara R,Eylenbosch W.Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium.Soc Sci Med 1993;37:173-181[PMID:8351532]
123 Jordan R,Law M.An appraisal of the efficacy and cost effectiveness of antenatal screening for hepatitis B.J Med Screen1997;4:117-127[PMID:9368867]
124 Dwyer MJ,McIntyre PG.Ante-natal screening for hepatitis B surface antigen:an appraisal of its value in a low prevalence area.Epidemiol Infect 1996;117:121-131[PMID:8760959]
125 Audet AM,Delage G,Remis RS.Screening for HBsAg in pregnant women:a cost analysis of the universal screening policy in the province of Quebec.Can J Public Health 1991;82:191 -195[PMID:1909210]
126 Thomas IL.Cost effectiveness of antenatal hepatitis B screening and vaccination of infants.Aust N Z J Obstet Gynaecol 1990;30:331-335[PMID:2150586]
127 Eckman MH,Kaiser TE,Sherman KE.The cost-effectiveness of screening for chronic hepatitis B infection in the United States.Clin Infect Dis 2011;52:1294-1306[PMID:21540206DOI:10.1093/cid/cir199]
128 Williams R,Holt AP.Screening immigrants for tuberculosis--why not for HBV infectionLancet 2013;381:2164-2165[PMID:23791343 DOI:10.1016/S0140-6736(13)61438-5]
129 Pendleton S,Wilson-Webb P.Rising curve:chronic hepatitis B infection in the UK.Available from:URL:http://www.hepb.org.uk/information/resources/rising_curve_chronic_hepatitis_b_infection_in_the_uk/risin g_curve.pdf
130 Tedder RS,Rodger AJ,Fries L,Ijaz S,Thursz M,Rosenberg W,Naoumov N,Banatvala J,Williams R,Dusheiko G,Chokshi S,Wong T,Rosenberg G,Moreea S,Bassendine M,Jacobs M,Mills PR,Mutimer D,Ryder SD,Bathgate A,Hussaini H,Dillon JF,Wright M,Bird G,Collier J,Anderson M,Johnson AM.The diversity and management of chronic hepatitis B virus infections in the United Kingdom:a wake-up call.Clin Infect Dis 2013;56:951-960[PMID:23223601 DOI:10.1093/cid/cis1013]
131 Beutels M,Van Damme P,Aelvoet W,Desmyter J,Dondeyne F,Goilav C,Mak R,Muylle L,Pierard D,Stroobant A,Van Loock F,Waumans P,Vranckx R.Prevalence of hepatitis A,B and C in the Flemish population.Eur J Epidemiol 1997;13:275-280[PMID:9258525]
132 Roudot-Thoraval F,Kouadja F,Wirquin V,Thiers V,Avons P,Brechot C,Dhumeaux D.[Prevalence of HBs antigen carriers and markers of B virus replication in a population of pregnant women,in France].Gastroenterol Clin Biol 1989;13:353 -356[PMID:2737390]
133 Vall Mayans M,Arellano E,Armengol P,EscribàJM,Loureiro E,SaladiéP,Sanz B,Saravanya M,Vall M,Villena MJ.[HIV infection and other sexually-transmitted infections among immigrants in Barcelona].Enferm Infecc Microbiol Clin2002;20:154-156[PMID:11996700]
134 Panagopoulos P,Economou A,Kasimi A,Spyropoulou P,Kanellopoulos N,Dadiotis L,Salamalekis E.Prevalence of hepatitis B and C in the maternity department of a Greek district hospital.J Matern Fetal Neonatal Med 2004;16:106-110[PMID:15512720]
135 Stroffolini T,Bianco E,Szklo A,Bernacchia R,Bove C,Colucci M,Cristina Coppola R,D’Argenio P,Lopalco P,Parlato A,Ragni P,Simonetti A,Zotti C,Mele A.Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy.Vaccine 2003;21:1246-1249[PMID:12559805]
136 France AM,Bornschlegel K,Lazaroff J,Kennedy J,Balter S.Estimating the prevalence of chronic hepatitis B virus infection--New York City,2008.J Urban Health 2012;89:373-383[PMID:22246675 DOI:10.1007/s11524011-9653-7]
137 Connolly MA,Gayer M,Ryan MJ,Salama P,Spiegel P,Heymann DL.Communicable diseases in complex emergencies:impact and challenges.Lancet 2004;364:1974-1983[PMID:15567014]
138 Gayer M,Legros D,Formenty P,Connolly MA.Conflict and emerging infectious diseases.Emerg Infect Dis 2007;13:1625-1631[PMID:18217543]
139 European Centre for Disease Control and Prevention(2010).Hepatitis B and C in the EU neighbourhood:prevalence,burden of disease and screening policies.Available from:URL:http://ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C_EU_neighbourhood.pdf
140 McDermott S,Desmeules M,Lewis R,Gold J,Payne J,Lafrance B,Vissandjée B,Kliewer E,Mao Y.Cancer incidence among Canadian immigrants,1980-1998:results from a national cohort study.J Immigr Minor Health 2011;13:15-26[PMID:20490685 DOI:10.1007/s10903-010-9347-3]
141 DesMeules M,Gold J,McDermott S,Cao Z,Payne J,Lafrance B,Vissandjée B,Kliewer E,Mao Y.Disparities in mortality patterns among Canadian immigrants and refugees,1980-1998:results of a national cohort study.J Immigr Health 2005;7:221-232[PMID:19813288]
142 Rein DB,Lesesne SB,Leese PJ,Weinbaum CM.Communitybased hepatitis B screening programs in the United States in 2008.J Viral Hepat 2010;17:28-33[PMID:19674286 DOI:10 .1111/j.1365-2893.2009.01165.x]
143 IOM(Institute of Medicine).2010.Hepatitis and Liver Cancer:A National Strategy for Prevention and Control of Hepatitis B and C.Washington,DC:The National Academies Press.Available from:URL:http://www.nap.edu/catalog/12793.html
144 Chironna M,Germinario C,Lopalco PL,Carrozzini F,Barbuti S,Quarto M.Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey.Infection 2003;31 :70-74[PMID:12682810]
145 Michos A,Terzidis A,Kalampoki V,Pantelakis K,Spanos T,Petridou ET.Seroprevalence and risk factors for hepatitis A,B,and C among Roma and non-Roma children in a deprived area of Athens,Greece.J Med Virol 2008;80:791-797[PMID:18360892]
146 Roussos A,Goritsas C,Pappas T,Spanaki M,Papadaki P,Ferti A.Prevalence of hepatitis B and C markers among refugees in Athens.World J Gastroenterol 2003;9:993-995[PMID:12717844]
147 Burnazian AI.[Japanese public health system in Southern Sakhalin in 1945(on the 30th anniversary of the victory over Japanese imperialism)].Sov Zdravookhr 1975;(10):63-67[PMID:1105797]
148 Palumbo E,Scotto G,Faleo G,Cibelli DC,Angarano G.Prevalence of HBV genotypes in South American immigrants affected by HBV-related chronic active hepatitis.Braz J Infect Dis 2007;11:311-313[PMID:17684630]
149 Palumbo E,Scotto G,Faleo G,Cibelli DC,Saracino A,Angarano G.Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis.Arq Gastroenterol2007;44:54-57[PMID:17639184]
150 Majori S,Baldo V,Tommasi I,Malizia M,Floreani A,Monteiro G,Ferrari A,Accordini A,Guzzo P,Baldovin T.Hepatitis A,B,and C infection in a community of sub-Saharan immigrants living in Verona(Italy).J Travel Med 2008;15:323-327[PMID:19006505 DOI:10.1111/j.1708-8305.2008.00230.x]
151 Palumbo E,Scotto G,Cibelli DC,Faleo G,Saracin A,Angarano G.Immigration and hepatitis B virus:epidemiological,clinical and therapeutic aspects.East Mediterr Health J 2008;14 :784-790[PMID:19166160]
152 Manzardo C,Trevio B,Gómez i Prat J,Cabezos J,MonguíE,Clavería I,Luis Del Val J,Zabaleta E,Zarzuela F,Navarro R.Communicable diseases in the immigrant population attended to in a tropical medicine unit:epidemiological aspects and public health issues.Travel Med Infect Dis 2008;6:4 -11[PMID:18342267 DOI:10.1016/j.tmaid.2007.11.002]
153 Aweis D,Brabin BJ,Beeching NJ,Bunn JE,Cooper C,Gardner K,Iriyagolle C,Hart CA.Hepatitis B prevalence and risk factors for HBsAg carriage amongst Somali households in Liverpool.Commun Dis Public Health 2001;4:247-252[PMID:12109390]
154 Chironna M,Germinario C,Lopalco PL,Carrozzini F,Quarto M.Prevalence of hepatitis virus infections in Kosovar refugees.Int J Infect Dis 2001;5:209-213[PMID:11953219]
155 Veldhuijzen IK,van Driel HF,Vos D,de Zwart O,van Doornum GJ,de Man RA,Richardus JH.Viral hepatitis in a multi-ethnic neighborhood in the Netherlands:results of a community-based study in a low prevalence country.Int J Infect Dis 2009;13:e9-e13[PMID:18678518 DOI:10.1016/j.ijid.2008.05]
156 Cowan SA,Bagdonaite J,Qureshi K.Universal hepatitis B screening of pregnant women in Denmark ascertains substantial additional infections:results from the first five months.Euro Surveill 2006;11:E060608.3[PMID:16819119]
157 Keane FE,Neale J,Phillips T,Heard L,Jones R,Guttridge B,Bendall R.Offering routine antenatal testing for HIV and hepatitis B in the rural setting of Cornwall.Sex Transm Infect2002;78:133-134[PMID:12081176]
158 Universal antenatal screening for hepatitis B and immunisation of babies at risk.Commun Dis Rep CDR Wkly 1998;8:281,284 [PMID:9745169]
159 Stroffolini T,Pasquini P.Five years of vaccination campaign against hepatitis B in Italy in infants of hepatitis B surface antigen carrier mothers.Ital J Gastroenterol 1990;22:195-197[PMID:2131945]
160 Loubière S,Rotily M,Moatti JP.Prevention could be less cost-effective than cure:the case of hepatitis C screening policies in France.Int J Technol Assess Health Care 2003;19:632 -645[PMID:15095769]
161 Papaevangelou V,Hadjichristodoulou C,Cassimos D,Theodoridou M.Adherence to the screening program for HBV infection in pregnant women delivering in Greece.BMC Infect Dis 2006;6:84[PMID:16681862]
162 Adamo B,Stroffolini T,Sagliocca L,Simonetti A,Iadanza F,Fossi E,Tancredi F,Mele A.Ad hoc survey of hepatitis B vaccination campaign in newborns of HBsAg positive mothers and in 12-year-old subjects in southern Italy.Vaccine1998;16:775-777[PMID:9627934]
163 Bonura F,Sorgi M,Perna AM,Puccio G,Tramuto F,Cajozzo C,Romano N,Vitale F.Pregnant women as a sentinel population to target and implement hepatitis B virus(HBV)vaccine coverage:a three-year survey in Palermo,Sicily.Vaccine2005;23:3243-3246[PMID:15837228]
164 Beckers K,Schaad UB,Heininger U.Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns.Eur J Pediatr 2004;163:654-657[PMID:15316775]
165 van Steenbergen JE,Leentvaar-Kuijpers A,Baayen D,Dukers HT,van Doornum GJ,van den Hoek JA,Coutinho RA.Evaluation of the hepatitis B antenatal screening and neonatal immunization program in Amsterdam,1993-1998.Vaccine2001;20:7-11[PMID:11567738]
166 Bracebridge S,Irwin D,Millership S.Prevention of perinatal hepatitis B transmission in a health authority area:an audit.Commun Dis Public Health 2004;7:138-141[PMID:15259417]
167 Lauer GM,Walker BD.Hepatitis C virus infection.N Engl J Med 2001;345:41-52[PMID:11439948]
168 van der Poel CL,Janssen MP,Borkent-Raven B.The collection,testing and use of blood and blood products in Europe in 2005.Europe:Final Report for the Council of Europe,2009
169 Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection,testing,processing,storage and distribution of human blood and blood components and amending Directive 2001/83/EC.Europa:Summaries of EU legislation,2002
170 Winstock AR,Sheridan J,Lovell S,Farrell M,Strang J.National survey of hepatitis testing and vaccination services provided by drug services in England and Wales.Eur J Clin Microbiol Infect Dis 2000;19:823-828[PMID:11152306]
171 van Steenbergen JE.Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands(1998-2000)among men who have sex with men,hard drug users,sex workers and heterosexual persons with multiple partners.J Hepatol 2002;37:507-513[PMID:12217605]
172 Centers for Disease Control and Prevention(CDC).Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students.MMWR Recomm Rep 2012;61:1-12[PMID:22763928]
173 Tillmann HL,Zachou K,Dalekos GN.Management of severe acute to fulminant hepatitis B:to treat or not to treat or when to treatLiver Int 2012;32:544-553[PMID:22099371DOI:10.1111/j.1478-3231.2011.02682.x]
174 Fattovich G,Giustina G,Sanchez-Tapias J,Quero C,Mas A,Olivotto PG,Solinas A,Almasio P,Hadziyannis S,Degos F,de Moura MC,Krogsgaard K,Pantalena M,Realdi G,Corrocher R,Schalm SW.Delayed clearance of serum HBsAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis.European Concerted Action on Viral Hepatitis(EUROHEP)Am J Gastroenterol 1998;93:896-900[PMID:9647014]
175 Perrillo R,Hou J,Papatheodoridis G,Manns M.Patient management and clinical decision making in HBV--aims of therapy and what we can achieve.Antivir Ther 2010;15Suppl 3:45-51[PMID:21041903 DOI:10.3851/IMP1623]
176 Li WC,Wang MR,Kong LB,Ren WG,Zhang YG,Nan YM.Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion:a metaanalysis of controlled clinical trials.BMC Infect Dis 2011;11:165 [PMID:21651820 DOI:10.1186/1471-2334-11-165]
177 Niederau C,Heintges T,Lange S,Goldmann G,Niederau CM,Mohr L,Hussinger D.Long-term follow-up of HBeAgpositive patients treated with interferon alfa for chronic hepatitis B.N Engl J Med 1996;334:1422-1427[PMID:8618580]
178 Brunetto MR,Oliveri F,Coco B,Leandro G,Colombatto P,Gorin JM,Bonino F.Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients:a long term cohort study.J Hepatol 2002;36:263-270[PMID:11830339]
179 Chu CJ,Hussain M,Lok AS.Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection.Hepatology 2002;36:1408-1415[PMID:12447866]
180 Lai M,Hyatt BJ,Nasser I,Curry M,Afdhal NH.The clinical significance of persistently normal ALT in chronic hepatitis B infection.J Hepatol 2007;47:760-767[PMID:17928090]
181 Chu CM,Liaw YF.Chronic hepatitis B virus infection acquired in childhood:special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.J Viral Hepat 2007;14:147-152[PMID:17305879]
182 Liaw YF,Chu CM,Su IJ,Huang MJ,Lin DY,Chang-Chien CS.Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.Gastroenterology 1983;84:216-219[PMID:6848402]
183 Lok AS,Lai CL,Wu PC,Leung EK,Lam TS.Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection.Gastroenterology 1987;92:1839-1843[PMID:3569757]
184 Lok AS,Lai CL.Acute exacerbations in Chinese patients with chronic hepatitis B virus(HBV)infection.Incidence,predisposing factors and etiology.J Hepatol 1990;10:29-34[PMID:2307827]
185 Liaw YF,Tai DI,Chu CM,Pao CC,Chen TJ.Acute exacerbation in chronic type B hepatitis:comparison between HBeAg and antibody-positive patients.Hepatology 1987;7:20-23[PMID:2433203]
186 Han KH,Kim DY.Chronic HBV infection with persistently normal ALT:not to treat.Hepatol Int 2008;2:185-189[DOI:10 .1007/s12072-008-9068-z]
187 Papatheodoridis GV,Manolakopoulos S,Liaw YF,Lok A.Follow-up and indications for liver biopsy in HBeAgnegative chronic hepatitis B virus infection with persistently normal ALT:a systematic review.J Hepatol 2012;57:196-202[PMID:22450396 DOI:10.1016/j.jhep.2011.11.030]
188 Wong GL,Wong VW,Choi PC,Chan AW,Chan HL.Development of a non-invasive algorithm with transient elastography(Fibroscan)and serum test formula for advanced liver fibrosis in chronic hepatitis B.Aliment Pharmacol Ther 2010;31:1095-1103[PMID:20180785 DOI:10.1111/j.13652036.2010.04276.x]
189 Fung J,Lai CL,Seto WK,Yuen MF.The use of transient elastography in the management of chronic hepatitis B.Hepatol Int 2011;Epub ahead of print[PMID:21695588]
190 Shim JH,Lee HC,Kim KM,Lim YS,Chung YH,Lee YS,Suh DJ.Efficacy of entecavir in treatment-nave patients with hepatitis B virus-related decompensated cirrhosis.J Hepatol 2010;52:176-182[PMID:20006394 DOI:10.1016/j.jhep.2009.11.007]
191 Liaw YF,Raptopoulou-Gigi M,Cheinquer H,Sarin SK,Tanwandee T,Leung N,Peng CY,Myers RP,Brown RS,Jeffers L,Tsai N,Bialkowska J,Tang S,Beebe S,Cooney E.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation:a randomized,openlabel study.Hepatology 2011;54:91-100[PMID:21503940DOI:10.1002/hep.24361]
192 Reijnders JG,Perquin MJ,Zhang N,Hansen BE,Janssen HL.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.Gastroenterology 2010;139:491-498[PMID:20381492DOI:10.1053/j.gastro.2010.03.059]
193 van Nunen AB,Hansen BE,Suh DJ,Lhr HF,Chemello L,Fontaine H,Heathcote J,Song BC,Janssen HL,de Man RA,Schalm SW.Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.Gut 2003;52:420-424[PMID:12584227]
194 Lee HW,Lee HJ,Hwang JS,Sohn JH,Jang JY,Han KJ,Park JY,Kim do Y,Ahn SH,Paik YH,Lee CK,Lee KS,Chon CY,Han KH.Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.Hepatology 2010;51:415-421[PMID:19902424 DOI:10.1002/hep.23323]
195 Song BC,Suh DJ,Lee HC,Chung YH,Lee YS.Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.Hepatology2000;32:803-806[PMID:11003626]
196 Dienstag JL,Cianciara J,Karayalcin S,Kowdley KV,Willems B,Plisek S,Woessner M,Gardner S,Schiff E.Durability of serologic response after lamivudine treatment of chronic hepatitis B.Hepatology 2003;37:748-755[PMID:12668966]
197 Yoon SK,Jang JW,Kim CW,Bae SH,Choi JY,Choi SW,Lee YS,Lee CD,Chung KW,Sun HS,Kim BS.Long-term results of lamivudine monotherapy in Korean patients with HBeAgpositive chronic hepatitis B:response and relapse rates,and factors related to durability of HBeAg seroconversion.Intervirology 2005;48:341-349[PMID:16024938]
198 Wu IC,Shiffman ML,Tong MJ,Marcellin P,Mondou E,Lok D,Trihn HN,Carosi G,Akarca US,Gadano A,Habersetzer F.Entecavir(ETV)monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir(TDF)in nucleos(t)ide naive patients with chronic hepatitis B:the BELOW study.Hepatology 2011;54:471A
199 Cooksley WG,Piratvisuth T,Lee SD,Mahachai V,Chao YC,Tanwandee T,Chutaputti A,Chang WY,Zahm FE,Pluck N.Peginterferon alpha-2a(40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat 2003;10:298-305[PMID:12823597]
200 Zhao H,Kurbanov F,Wan MB,Yin YK,Niu JQ,Hou JL,Wei L,Wang GQ,Tanaka Y,Mizokami M,Si CW.Genotype B and younger patient age associated with better response to low-dose therapy:a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.Clin Infect Dis 2007;44:541 -548[PMID:17243057]
201 Chan HL,Leung NW,Hui AY,Wong VW,Liew CT,Chim AM,Chan FK,Hung LC,Lee YT,Tam JS,Lam CW,Sung JJ.A randomized,controlled trial of combination therapy for chronic hepatitis B:comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.Ann Intern Med2005;142:240-250[PMID:15710957]
202 Cao ZH,Ma LN,Zhang HW,Liu YL,Chen XY.Extended treatment with peginterferonα-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.J Dig Dis 2013;14:446-450[PMID:23615131 DOI:10.1111/1751-2980.12065]
203 Buster EH,Flink HJ,Cakaloglu Y,Simon K,Trojan J,Tabak F,So TM,Feinman SV,Mach T,Akarca US,Schutten M,Tielemans W,van Vuuren AJ,Hansen BE,Janssen HL.Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2 b.Gastroenterology 2008;135:459-467[PMID:18585385 DOI:10 .1053/j.gastro.2008.05.031]
204 Wong VW,Wong GL,Yan KK,Chim AM,Chan HY,Tse CH,Choi PC,Chan AW,Sung JJ,Chan HL.Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.Hepatology 2010;51:1945-1953[PMID:20209602 DOI:10.1002/hep.23568]
205 Liaw YF,Sheen IS,Lee CM,Akarca US,Papatheodoridis GV,Suet-Hing Wong F,Chang TT,Horban A,Wang C,Kwan P,Buti M,Prieto M,Berg T,Kitrinos K,Peschell K,Mondou E,Frederick D,Rousseau F,Schiff ER.Tenofovir disoproxil fumarate(TDF),emtricitabine/TDF,and entecavir in patients with decompensated chronic hepatitis B liver disease.Hepatology 2011;53:62-72[PMID:21254162 DOI:10.1002/hep.23952]
206 Lau GK,Piratvisuth T,Luo KX,Marcellin P,Thongsawat S,Cooksley G,Gane E,Fried MW,Chow WC,Paik SW,Chang WY,Berg T,Flisiak R,McCloud P,Pluck N.Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med 2005;352:2682-2695[PMID:15987917]
207 Janssen HL,van Zonneveld M,Senturk H,Zeuzem S,Akarca US,Cakaloglu Y,Simon C,So TM,Gerken G,de Man RA,Niesters HG,Zondervan P,Hansen B,Schalm SW.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial.Lancet 2005;365:123-129[PMID:15639293]
208 Lai CL,Chien RN,Leung NW,Chang TT,Guan R,Tai DI,Ng KY,Wu PC,Dent JC,Barber J,Stephenson SL,Gray DF.A one-year trial of lamivudine for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group.N Engl J Med 1998;339:61 -68[PMID:9654535]
209 Dienstag JL,Schiff ER,Wright TL,Perrillo RP,Hann HW,Goodman Z,Crowther L,Condreay LD,Woessner M,Rubin M,Brown NA.Lamivudine as initial treatment for chronic hepatitis B in the United States.N Engl J Med 1999;341:1256-1263[PMID:10528035]
210 Chang TT,Gish RG,de Man R,Gadano A,Sollano J,Chao YC,Lok AS,Han KH,Goodman Z,Zhu J,Cross A,DeHertogh D,Wilber R,Colonno R,Apelian D;BEHoLD AI463022 Study Group.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med2006;354:1001-1010[PMID:16525137]
211 Lai CL,Gane E,Liaw YF,Hsu CW,Thongsawat S,Wang Y,Chen Y,Heathcote EJ,Rasenack J,Bzowej N,Naoumov NV,Di Bisceglie AM,Zeuzem S,Moon YM,Goodman Z,Chao G,Constance BF,Brown NA;Globe Study Group.Telbivudine versus lamivudine in patients with chronic hepatitis B.N Engl J Med 2007;357:2576-2588[PMID:18094378]
212 Marcellin P,Chang TT,Lim SG,Tong MJ,Sievert W,Shiffman ML,Jeffers L,Goodman Z,Wulfsohn MS,Xiong S,Fry J,Brosgart CL.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med 2003;348 :808-816[PMID:12606735]
213 Marcellin P,Heathcote EJ,Buti M,Gane E,de Man RA,Krastev Z,Germanidis G,Lee SS,Flisiak R,Kaita K,Manns M,Kotzev I,Tchernev K,Buggisch P,Weilert F,Kurdas OO,Shiffman ML,Trinh H,Washington MK,Sorbel J,Anderson J,Snow-Lampart A,Mondou E,Quinn J,Rousseau F.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.N Engl J Med 2008;359:2442-2455[PMID:19052126]
214 Liaw YF,Jia JD,Chan HL,Han KH,Tanwandee T,Chuang WL,Tan DM,Chen XY,Gane E,Piratvisuth T,Chen L,Xie Q,Sung JJ,Wat C,Bernaards C,Cui Y,Marcellin P.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.Hepatology 2011;54 :1591-1599[PMID:22045673 DOI:10.1002/hep.24555]
215 van Zonneveld M,Honkoop P,Hansen BE,Niesters HG,Darwish Murad S,de Man RA,Schalm SW,Janssen HL.Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.Hepatology 2004;39:804-810[PMID:14999700]
216 Liaw YF,Leung NW,Chang TT,Guan R,Tai DI,Ng KY,Chien RN,Dent J,Roman L,Edmundson S,Lai CL.Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.Asia Hepatitis Lamivudine Study Group.Gastroenterology 2000;119:172-180[PMID:10889166]
217 Lok AS,Lai CL,Leung N,Yao GB,Cui ZY,Schiff ER,Dienstag JL,Heathcote EJ,Little NR,Griffiths DA,Gardner SD,Castiglia M.Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Gastroenterology 2003;125:1714-1722[PMID:14724824]
218 Leung NW,Lai CL,Chang TT,Guan R,Lee CM,Ng KY,Lim SG,Wu PC,Dent JC,Edmundson S,Condreay LD,Chien RN.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy.Hepatology 2001;33:1527-1532[PMID:11391543]
219 Marcellin P,Chang TT,Lim SG,Sievert W,Tong M,Arterburn S,Borroto-Esoda K,Frederick D,Rousseau F.Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.Hepatology 2008;48:750-758[PMID:18752330 DOI:10.1002/hep.22414]
220 Liaw YF,Gane E,Leung N,Zeuzem S,Wang Y,Lai CL,Heathcote EJ,Manns M,Bzowej N,Niu J,Han SH,Hwang SG,Cakaloglu Y,Tong MJ,Papatheodoridis G,Chen Y,Brown NA,Albanis E,Galil K,Naoumov NV.2-Year GLOBE trial results:telbivudine Is superior to lamivudine in patients with chronic hepatitis B.Gastroenterology 2009;136:486-495[PMID:19027013 DOI:10.1053/j.gastro.2008.10.026]
221 Chang TT,Lai CL,Kew Yoon S,Lee SS,Coelho HS,Carrilho FJ,Poordad F,Halota W,Horsmans Y,Tsai N,Zhang H,Tenney DJ,Tamez R,Iloeje U.Entecavir treatment for up to5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.Hepatology 2010;51:422-430[PMID:20049753DOI:10.1002/hep.23327]
222 Yuen MF,Seto WK,Fung J,Wong DK,Yuen JC,Lai CL.Three years of continuous entecavir therapy in treatmentnave chronic hepatitis B patients:VIRAL suppression,viral resistance,and clinical safety.Am J Gastroenterol 2011;106:1264-1271[PMID:21364549 DOI:10.1038/ajg.2011.45]
223 Kitrinos KM,Corsa A,Liu Y,Flaherty J,Snow-Lampart A,Marcellin P,Borroto-Esoda K,Miller MD.No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.Hepatology 2014;59 :434-442[PMID:23939953 DOI:10.1002/hep.26686]
224 Heathcote EJ,Marcellin P,Buti M,Gane E,De Man RA,Krastev Z,Germanidis G,Lee SS,Flisiak R,Kaita K,Manns M,Kotzev I,Tchernev K,Buggisch P,Weilert F,Kurdas OO,Shiffman ML,Trinh H,Gurel S,Snow-Lampart A,BorrotoEsoda K,Mondou E,Anderson J,Sorbel J,Rousseau F.Threeyear efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.Gastroenterology 2011;140:132 -143[PMID:20955704 DOI:10.1053/j.gastro.2010.10.011]
225 Marcellin P,Lau GK,Bonino F,Farci P,Hadziyannis S,Jin R,Lu ZM,Piratvisuth T,Germanidis G,Yurdaydin C,Diago M,Gurel S,Lai MY,Button P,Pluck N.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med2004;351:1206-1217[PMID:15371578]
226 Marcellin P,Avila C,Wursthorn K,Chuang WL,Lau GK,Peng CY.Telbivudine(LDT)plus peginterferon(PEGIFN)in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy(PN).J Hepatol 2010;52 :S6-S7[DOI:10.1016/S0168-8278(10)60015-3]
227 Gane E,Jia J,Han K,Tanwandee T,Chuang WL,Chuang WL.Neptune study:on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients.J Hepatol2011;54:S31
228 Sonneveld MJ,Rijckborst V,Boucher CA,Hansen BE,Janssen HL.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.Hepatology 2010;52:1251-1257[PMID:20830787 DOI:10.1002/hep.23844]
229 Piratvisuth T,Lau G,Chao YC,Jin R,Chutaputti A,Zhang QB,Tanwandee T,Button P,Popescu M.Sustained response to peginterferon alfa-2a(40 kD)with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.Hepatol Int 2008;2:102-110[PMID:19669285]
230 Gish RG,Chang TT,Lai CL,de Man R,Gadano A,Poordad F,Yang J,Brett-Smith H,Tamez R.Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-nave HBeAg-positive patients with chronic hepatitis B.J Viral Hepat 2010;17:16-22[PMID:19622117 DOI:10.1111/j.1365-2893.2009.01146.x]
231 Tassopoulos NC,Volpes R,Pastore G,Heathcote J,Buti M,Goldin RD,Hawley S,Barber J,Condreay L,Gray DF.Efficacy of lamivudine in patients with hepatitis B e antigennegative/hepatitis B virus DNA-positive(precore mutant)chronic hepatitis B.Lamivudine Precore Mutant Study Group.Hepatology 1999;29:889-896[PMID:10051494]
232 Rijckborst V,Hansen BE,Ferenci P,Brunetto MR,Tabak F,Cakaloglu Y,Lanza AG,Messina V,Iannacone C,Massetto B,Regep L,Colombo M,Janssen HL,Lampertico P.Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.J Hepatol 2012;56:1006-1011[PMID:22245886 DOI:10 .1016/j.jhep.2011.12.007]
233 Brunetto MR,Moriconi F,Bonino F,Lau GK,Farci P,Yurdaydin C,Piratvisuth T,Luo K,Wang Y,Hadziyannis S,Wolf E,McCloud P,Batrla R,Marcellin P.Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.Hepatology2009;49:1141-1150[PMID:19338056 DOI:10.1002/hep.22760]
234 Lai CL,Shouval D,Lok AS,Chang TT,Cheinquer H,Goodman Z,DeHertogh D,Wilber R,Zink RC,Cross A,Colonno R,Fernandes L.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N Engl J Med 2006;354 :1011-1020[PMID:16525138]
235 Lok AS,Hussain M,Cursano C,Margotti M,Gramenzi A,Grazi GL,Jovine E,Benardi M,Andreone P.Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.Hepatology 2000;32:1145-1153[PMID:11050068]
236 Hadziyannis SJ,Papatheodoridis GV,Dimou E,Laras A,Papaioannou C.Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Hepatology 2000;32:847-851[PMID:11003633]
237 Papatheodoridis GV,Dimou E,Laras A,Papadimitropoulos V,Hadziyannis SJ.Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Hepatology 2002;36:219-226[PMID:12085368]
238 Di Marco V,Marzano A,Lampertico P,Andreone P,Santantonio T,Almasio PL,Rizzetto M,CraxìA.Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.Hepatology 2004;40:883-891[PMID:15382125]
239 Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,Chang TT,Kitis G,Rizzetto M,Marcellin P,Lim SG,Goodman Z,Ma J,Brosgart CL,Borroto-Esoda K,Arterburn S,Chuck SL.Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.Gastroenterology 2006;131 :1743-1751[PMID:17087951]
240 Gane EJ,Wang Y,Liaw YF,Hou J,Thongsawat S,Wan M,Moon YM,Jia J,Chao YC,Niu J,Leung N,Samuel D,Hsu CW,Bao W,Lopez P,Avila C.Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.Liver Int 2011;31:676-684[PMID:21457439 DOI:10 .1111/j.14783231.2011.02490.x]
241 Lok AS,Trinh H,Carosi G,Akarca US,Gadano A,Habersetzer F,Sievert W,Wong D,Lovegren M,Cohen D,Llamoso C.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-nave patients with chronic hepatitis B.Gastroenterology 2012;143:619-628.e1[PMID:22643350]
242 Schiff E,Simsek H,Lee WM,Chao YC,Sette H,Janssen HL,Han SH,Goodman Z,Yang J,Brett-Smith H,Tamez R.Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.Am J Gastroenterol 2008;103:2776-2783[PMID:18721244 DOI:10 .1111/j.1572-0241.2008.02086.x]
243 Buti M,Hadziyannis S,Mathurin P,Urbanek P,Sherman M,Strasser S.Tenofovir disoproxil fumarate is highly active for treatment of chronic hepatitis B in subjects with cirrhosis.J Hepatol 2008;48:S33
244 Ha NB,Ha NB,Garcia RT,Trinh HN,Vu AA,Nguyen HA,Nguyen KK,Levitt BS,Nguyen MH.Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil.Hepatology 2009;50:727-734[PMID:19517525 DOI:10.1002/hep.23044]
245 Liaw YF,Sung JJ,Chow WC,Farrell G,Lee CZ,Yuen H,Tanwandee T,Tao QM,Shue K,Keene ON,Dixon JS,Gray DF,Sabbat J.Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med 2004;351:1521-1531[PMID:15470215]
246 Papatheodoridis GV,Dimou E,Dimakopoulos K,Manolakopoulos S,Rapti I,Kitis G,Tzourmakliotis D,Manesis E,Hadziyannis SJ.Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.Hepatology 2005;42:121-129[PMID:15962291]
247 Fontana RJ,Hann HW,Perrillo RP,Vierling JM,Wright T,Rakela J,Anschuetz G,Davis R,Gardner SD,Brown NA.Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.Gastroenterology 2002;123:719-727[PMID:12198698]
248 Papatheodoridis GV,Cholongitas E,Archimandritis AJ,Burroughs AK.Current management of hepatitis B virus infection before and after liver transplantation.Liver Int 2009;29:1294-1305[PMID:19619264 DOI:10.1111/j.14783231.2009.02085.x]
249 Grellier L,Mutimer D,Ahmed M,Brown D,Burroughs AK,Rolles K,McMaster P,Beranek P,Kennedy F,Kibbler H,McPhillips P,Elias E,Dusheiko G.Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.Lancet 1996;348:1212-1215[PMID:8898039]
250 Papatheodoridis GV,Lampertico P,Manolakopoulos S,Lok A.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review.J Hepatol 2010;53:348-356[PMID:20483498 DOI:10 .1016/j.jhep.2010.02.035]
251 Ferlay J,Shin HR,Bray F,Forman D,Mathers C,Parkin DM.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008.Int J Cancer 2010;127:2893-2917[PMID:21351269DOI:10.1002/ijc.25516]
252 El-Serag HB,Davila JA.Surveillance for hepatocellular carcinoma:in whom and howTherap Adv Gastroenterol 2011;4:5 -10[PMID:21317990 DOI:10.1177/1756283X10385964]
253 El-Serag HB,Siegel AB,Davila JA,Shaib YH,CaytonWoody M,McBride R,McGlynn KA.Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States:a population-based study.J Hepatol 2006;44:158-166[PMID:16290309]
254 Bruix J,Sherman M.Management of hepatocellular carcinoma.Hepatology 2005;42:1208-1236[PMID:16250051]
255 EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma.Eur J Cancer 2012;48:599-641[PMID:22424278 DOI:10.1016/j.ejca.2011.12.021]
256 Bruix J,Sherman M.American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update.Hepatology 2011;53:1020-1022[DOI:10.1002/hep.24199]
257 Omata M,Lesmana LA,Tateishi R,Chen PJ,Lin SM,Yoshida H,Kudo M,Lee JM,Choi BI,Poon RT,Shiina S,Cheng AL,Jia JD,Obi S,Han KH,Jafri W,Chow P,Lim SG,Chawla YK,Budihusodo U,Gani RA,Lesmana CR,Putranto TA,Liaw YF,Sarin SK.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Hepatol Int 2010;4:439-474[PMID:20827404 DOI:10 .1007/s12072-010-9165-7]
258 Zhang BH,Yang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol 2004;130:417-422[PMID:15042359]
259 Bolondi L.Screening tests for hepatocellular carcinoma.Hepatology 2003;37:1493;author reply 1493[PMID:12774028]
260 Kim CK,Lim JH,Lee WJ.Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver:accuracy of ultrasonography in transplant patients.J Ultrasound Med2001;20:99-104[PMID:11211142]
261 CraxìA,CammàC.Prevention of hepatocellular carcinoma.Clin Liver Dis 2005;9:329-46,viii[PMID:15831277]
262 Singal A,Volk ML,Waljee A,Salgia R,Higgins P,Rogers MA,Marrero JA.Meta-analysis:surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.Aliment Pharmacol Ther 2009;30:37-47[PMID:19392863 DOI:10.1111/j.1365-2036.2009.04014.x]
263 Sato T,Tateishi R,Yoshida H,Ohki T,Masuzaki R,Imamura J,Goto T,Kanai F,Obi S,Kato N,Shiina S,Kawabe T,Omata M.Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C.Hepatol Int 2009;3:544-550[PMID:19669240 DOI:10.1007/s12072-009-9145-y]
264 Tsukuma H,Hiyama T,Tanaka S,Nakao M,Yabuuchi T,Kitamura T,Nakanishi K,Fujimoto I,Inoue A,Yamazaki H.Risk factors for hepatocellular carcinoma among patients with chronic liver disease.N Engl J Med 1993;328:1797-1801[PMID:7684822]
265 McMahon BJ,Bulkow L,Harpster A,Snowball M,Lanier A,Sacco F,Dunaway E,Williams J.Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B:a 16-year population-based study.Hepatology 2000;32:842 -846[PMID:11003632]
266 Di Bisceglie AM,Sterling RK,Chung RT,Everhart JE,Dienstag JL,Bonkovsky HL,Wright EC,Everson GT,Lindsay KL,Lok AS,Lee WM,Morgan TR,Ghany MG,Gretch DR.Serum alpha-fetoprotein levels in patients with advanced hepatitis C:results from the HALT-C Trial.J Hepatol 2005;43:434 -441[PMID:16136646]
267 Yamashita T,Forgues M,Wang W,Kim JW,Ye Q,Jia H,Budhu A,Zanetti KA,Chen Y,Qin LX,Tang ZY,Wang XW.EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.Cancer Res2008;68:1451-1461[PMID:18316609 DOI:10.1158/0008-5472.CAN-07-6013]
268 Villanueva A,Minguez B,Forner A,Reig M,Llovet JM.Hepatocellular carcinoma:novel molecular approaches for diagnosis,prognosis,and therapy.Annu Rev Med2010;61:317-328[PMID:20059340 DOI:10.1146/annurev.med.080608.100623]
269 Szefler SJ.Leukotriene modifiers:what is their position in asthma therapyJ Allergy Clin Immunol 1998;102:170-172[PMID:9723656 DOI:10.1158/0008-5472.CAN-09-1089]
270 Trevisani F,D’Intino PE,Morselli-Labate AM,Mazzella G,Accogli E,Caraceni P,Domenicali M,De Notariis S,Roda E,Bernardi M.Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:influence of HBsAg and anti-HCV status.J Hepatol 2001;34:570 -575[PMID:11394657]
271 Chen JG,Parkin DM,Chen QG,Lu JH,Shen QJ,Zhang BC,Zhu YR.Screening for liver cancer:results of a randomised controlled trial in Qidong,China.J Med Screen 2003;10:204 -209[PMID:14738659]
272 El-Serag HB,Mason AC.Rising incidence of hepatocellular carcinoma in the United States.N Engl J Med 1999;340:745 -750[PMID:10072408]
273 Deuffic S,Buffat L,Poynard T,Valleron AJ.Modeling the hepatitis C virus epidemic in France.Hepatology 1999;29:1596-1601[PMID:10216148]
274 Barbara L,Benzi G,Gaiani S,Fusconi F,Zironi G,Siringo S,Rigamonti A,Barbara C,Grigioni W,Mazziotti A.Natural history of small untreated hepatocellular carcinoma in cirrhosis:a multivariate analysis of prognostic factors of tumor growth rate and patient survival.Hepatology 1992;16:132-137[PMID:1352268]
275 Ebara M,Ohto M,Shinagawa T,Sugiura N,Kimura K,Matsutani S,Morita M,Saisho H,Tsuchiya Y,Okuda K.Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis.A study in 22 patients.Gastroenterology 1986;90:289-298[PMID:2416627]
276 Sheu JC,Sung JL,Chen DS,Yang PM,Lai MY,Lee CS,Hsu HC,Chuang CN,Yang PC,Wang TH.Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.Gastroenterology 1985;89:259-266[PMID:2408960]
277 Santagostino E,Colombo M,Rivi M,Rumi MG,Rocino A,Linari S,Mannucci PM.A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus.Blood 2003;102:78-82[PMID:12649165]
278 Andersson KL,Salomon JA,Goldie SJ,Chung RT.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol 2008;6:1418-1424[PMID:18848905 DOI:10 .1016/j.cgh.2008.08.005]
279 Sangiovanni A,Del Ninno E,Fasani P,De Fazio C,Ronchi G,Romeo R,Morabito A,De Franchis R,Colombo M.Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.Gastroenterology 2004;126:1005-1014[PMID:15057740]
280 Trevisani F,De Notariis S,Rapaccini G,Farinati F,BenvegnùL,Zoli M,Grazi GL,Del PP,Di N,Bernardi M.Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma:effects on cancer stage and patient survival(Italian experience).Am J Gastroenterol 2002;97:734-744[PMID:11922571]
281 Santi V,Trevisani F,Gramenzi A,Grignaschi A,MiriciCappa F,Del Poggio P,Di Nolfo MA,BenvegnùL,Farinati F,Zoli M,Giannini EG,Borzio F,Caturelli E,Chiaramonte M,Bernardi M.Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.J Hepatol 2010;53:291-297[PMID:20483497 DOI:10.1016/j.jhep.2010.03.010]
282 Makuuchi M,Kokudo N,Arii S,Futagawa S,Kaneko S,Kawasaki S,Matsuyama Y,Okazaki M,Okita K,Omata M,Saida Y,Takayama T,Yamaoka Y.Development of evidencebased clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan.Hepatol Res 2008;38:37-51[PMID:18039202]
283 Nouso K,Tanaka H,Uematsu S,Shiraga K,Okamoto R,Onishi H,Nakamura S,Kobayashi Y,Araki Y,Aoki N,Shiratori Y.Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.J Gastroenterol Hepatol 2008;23:437-444[PMID:17683496]
284 Trinchet JC,Chaffaut C,Bourcier V,Degos F,Henrion J,Fontaine H,Roulot D,Mallat A,Hillaire S,Cales P,Ollivier I,Vinel JP,Mathurin P,Bronowicki JP,Vilgrain V,N’Kontchou G,Beaugrand M,Chevret S.Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis:a randomized trial comparing 3-and 6-month periodicities.Hepatology 2011;54:1987-1997[PMID:22144108 DOI:10.1002/hep.24545]
285 Fattovich G,Brollo L,Giustina G,Noventa F,Pontisso P,Alberti A,Realdi G,Ruol A.Natural history and prognostic factors for chronic hepatitis type B.Gut 1991;32:294-298[PMID:2013423]
286 Manno M,CammàC,Schepis F,Bassi F,Gelmini R,Giannini F,Miselli F,Grottola A,Ferretti I,Vecchi C,De Palma M,Villa E.Natural history of chronic HBV carriers in northern Italy:morbidity and mortality after 30 years.Gastroenterology2004;127:756-763[PMID:15362032]
287 Hsu YS,Chien RN,Yeh CT,Sheen IS,Chiou HY,Chu CM,Liaw YF.Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.Hepatology2002;35:1522-1527[PMID:12029639]
288 de Franchis R,Meucci G,Vecchi M,Tatarella M,Colombo M,Del Ninno E,Rumi MG,Donato MF,Ronchi G.The natural history of asymptomatic hepatitis B surface antigen carriers.Ann Intern Med 1993;118:191-194[PMID:8417636]
289 Sánchez-Tapias JM,Costa J,Mas A,Bruguera M,Rodés J.Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.Gastroenterology 2002;123:1848-1856[PMID:12454842]
290 Fattovich G.Natural history of hepatitis B.J Hepatol 2003;39Suppl 1:S50-S58[PMID:14708678]
291 Bellentani S,Tiribelli C,Saccoccio G,Sodde M,Fratti N,De Martin C,Cristianini G.Prevalence of chronic liver disease in the general population of northern Italy:the Dionysos Study.Hepatology 1994;20:1442-1449[PMID:7982643]
292 Evans AA,Chen G,Ross EA,Shen FM,Lin WY,London WT.Eight-year follow-up of the 90,000-person Haimen City cohort:I.Hepatocellular carcinoma mortality,risk factors,and gender differences.Cancer Epidemiol Biomarkers Prev 2002;11:369 -376[PMID:11927497]
293 Huo TI,Wu JC,Lee PC,Chau GY,Lui WY,Tsay SH,Ting LT,Chang FY,Lee SD.Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.Hepatology 1998;28:231-236[PMID:9657117]
294 Yuen MF,Wong DK,Sablon E,Tse E,Ng IO,Yuan HJ,Siu CW,Sander TJ,Bourne EJ,Hall JG,Condreay LD,Lai CL.HBsAg seroclearance in chronic hepatitis B in the Chinese:virological,histological,and clinical aspects.Hepatology 2004;39 :1694-1701[PMID:15185311]
295 Beasley RP,Hwang LY,Lin CC,Leu ML,Stevens CE,Szmuness W,Chen KP.Incidence of hepatitis B virus infections in preschool children in Taiwan.J Infect Dis 1982;146:198-204[PMID:7108271]
296 Villeneuve JP,Desrochers M,Infante-Rivard C,Willems B,Raymond G,Bourcier M,CtéJ,Richer G.A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal.Gastroenterology 1994;106:1000-1005[PMID:8143967]
297 Yu MW,Chang HC,Liaw YF,Lin SM,Lee SD,Liu CJ,Chen PJ,Hsiao TJ,Lee PH,Chen CJ.Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives.J Natl Cancer Inst 2000;92:1159-1164[PMID:10904089]
298 Kew MC,Marcus R,Geddes EW.Some characteristics of Mozambican Shangaans with primary hepatocellular cancer.S Afr Med J 1977;51:306-309[PMID:66757]
299 Kew MC,Macerollo P.Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks.Gastroenterology 1988;94:439-442[PMID:2446950]
300 Yuen MF,Tanaka Y,Fong DY,Fung J,Wong DK,Yuen JC,But DY,Chan AO,Wong BC,Mizokami M,Lai CL.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.J Hepatol 2009;50 :80-88[PMID:18977053 DOI:10.1016/j.jhep.2008.07.023]
301 Yang HI,Sherman M,Su J,Chen PJ,Liaw YF,Iloeje UH,Chen CJ.Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.J Clin Oncol 2010;28:2437-2444[PMID:20368541 DOI:10.1200/JCO.2009.27.4456]
302 Chen JD,Yang HI,Iloeje UH,You SL,Lu SN,Wang LY,Su J,Sun CA,Liaw YF,Chen CJ.Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liverrelated death.Gastroenterology 2010;138:1747-1754[PMID:20114048 DOI:10.1053/j.gastro.2010.01.042]
303 Wong GL,Chan HL,Mak CW,Lee SK,Ip ZM,Lam AT,Iu HW,Leung JM,Lai JW,Lo AO,Chan HY,Wong VW.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.Hepatology 2013;58:1537-1547[PMID:23389810 DOI:10.1002/hep.26301]
304 Sherman M.Does hepatitis B treatment reduce the incidence of hepatocellular carcinomaHepatology 2013;58:18-20[PMID:23401270 DOI:10.1002/hep.26317]
305 Tziomalos K.Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B.World J Hepatol 2010;2:91-93[PMID:21160979 DOI:10.4254/wjh.v2.i3.91]
306 Davila JA,Henderson L,Kramer JR,Kanwal F,Richardson PA,Duan Z,El-Serag HB.Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.Ann Intern Med 2011;154:85-93[PMID:21242365 DOI:10.7326/0003-4819-154-2-201101180-00006]
307 Davila JA,Morgan RO,Richardson PA,Du XL,McGlynn KA,El-Serag HB.Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.Hepatology 2010;52:132-141[PMID:20578139 DOI:10.1002/hep.23615]
308 Leykum LK,El-Serag HB,Cornell J,Papadopoulos KP.Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage,treatment received,and survival.Clin Gastroenterol Hepatol 2007;5:508-512[PMID:17382601]
309 Singal AG,Volk ML,Rakoski MO,Fu S,Su GL,McCurdy H,Marrero JA.Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma.J Clin Gastroenterol 2011;45:727-732[PMID:21602704DOI:10.1097/MCG.0b013e31820989d3]
310 Aberra FB,Essenmacher M,Fisher N,Volk ML.Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis.Dig Dis Sci 2013;58:1157-1160[PMID:23111632 DOI:10.1007/s10620-012-2461-4]
2 Blachier M,Leleu H,Peck-Radosavljevic M,Valla DC,Roudot-Thoraval F.The burden of liver disease in Europe.EASL2013.Available from:URL:http://www.easl.eu/assets/.../54 ae845caec619f_file.pdf
3 European Associations for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection.J Hepatol 2012;57:167-185[PMID:22436845]
4 Liaw YF,Kao JH,Piratvuth T,Chan HLY,Chien RN,Liu CJ.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update.Hepatol Int 2012;6:531-561[DOI 10.1007/s12072-012-9365-9364]
5 Lok AS,McMahon BJ.Chronic hepatitis B:update 2009.Hepatology 2009;50:661-662[PMID:19714720 DOI:10.1002/hep.23190]
6 Marcellin P,Gane E,Buti M,Afdhal N,Sievert W,Jacobson IM,Washington MK,Germanidis G,Flaherty JF,Schall RA,Bornstein JD,Kitrinos KM,Subramanian GM,McHutchison JG,Heathcote EJ.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a5 -year open-label follow-up study.Lancet 2013;381:468-475[PMID:23234725 DOI:10.1016/S0140-6736(12)61425-1]
7 Chang TT,Liaw YF,Wu SS,Schiff E,Han KH,Lai CL,Safadi R,Lee SS,Halota W,Goodman Z,Chi YC,Zhang H,Hindes R,Iloeje U,Beebe S,Kreter B.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.Hepatology 2010;52:886-893[PMID:20683932 DOI:10.1002/hep.23785]
8 Niro GA,Ippolito AM,Fontana R,Valvano MR,Gioffreda D,Iacobellis A,Merla A,Durazzo M,Lotti G,Di Mauro L,Andriulli A.Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.J Viral Hepat 2013;20:502-509[PMID:23730844 DOI:10 .1111/jvh.12054]
9 Kim CH,Um SH,Seo YS,Jung JY,Kim JD,Yim HJ,Keum B,Kim YS,Jeen YT,Lee HS,Chun HJ,Kim CD,Ryu HS.Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.J Gastroenterol Hepatol 2012;27:1589-1595[PMID:22554121 DOI:10.1111/j.1440-1746.2012.07167.x]
10 Papatheodoridis GV,Manolakopoulos S,Touloumi G,Vourli G,Raptopoulou-Gigi M,Vafiadis-Zoumbouli I,Vasiliadis T,Mimidis K,Gogos C,Ketikoglou I,Manesis EK.Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s)starting with lamivudine monotherapy:results of the nationwide HEPNET.Greece cohort study.Gut 2011;60:1109-1116[PMID:21270118 DOI:10.1136/gut.2010.221846]
11 Jin YJ,Shim JH,Lee HC,Yoo DJ,Kim KM,Lim YS,Suh DJ.Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.J Gastroenterol Hepatol 2011;26:1380-1388[PMID:21884247 DOI:10.1111/j.1440-1746.2011.06776.x]
12 Hosaka T,Suzuki F,Kobayashi M,Seko Y,Kawamura Y,Sezaki H,Akuta N,Suzuki Y,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Kumada H.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.Hepatology 2013;58:98-107[PMID:23213040 DOI:10.1002/hep.26180]
13 Zoutendijk R,Reijnders JG,Zoulim F,Brown A,Mutimer DJ,Deterding K,Hofmann WP,Petersen J,Fasano M,Buti M,Berg T,Hansen BE,Sonneveld MJ,Wedemeyer H,Janssen HL.Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.Gut 2013;62:760-765[PMID:22490523 DOI:10 .1136/gutjnl-2012-302024]
14 Singal AK,Salameh H,Kuo YF,Fontana RJ.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.Aliment Pharmacol Ther 2013;38:98-106[PMID:23713520 DOI:10.1111/apt.12344]
15 Cadranel JF,Lahmek P,Causse X,Bellaiche G,Bettan L,Fontanges T,Medini A,Henrion J,Chousterman M,Condat B,Hervio P,Periac P,Eugène C,Moindrot H,Grasset D,Nouel O,Pilette C,Szostak-Talbodec N,Cayla JM,Si-Ahmed SN,Dumouchel P,Pariente A,Lesgourgues B,Denis J.Epidemiology of chronic hepatitis B infection in France:risk factors for significant fibrosis--results of a nationwide survey.Aliment Pharmacol Ther 2007;26:565-576[PMID:17661760]
16 Mota A,Areias J,Cardoso MF.Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in northern Portugal with reference to the viral genotypes.J Med Virol 2011;83:71-77[PMID:21108341 DOI:10.1002/jmv.21939]
17 Larsen JJ.alpha And beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man.Br J Pharmacol 1979;65:215-222[PMID:216452 DOI:10.1111/j.14783231.2010.02373.x]
18 Almasio PL,CraxìA.Management of hepatitis B virus infection in the underprivileged world.Liver Int 2011;31:749-750[PMID:21645204 DOI:10.1111/j.1478-3231.2011.02477.x]
19 European Liver Patients Association.Report on hepatitis patient self-help in Europe;2010.Available from:URL:http://www.hepbcppa.org/wp-content/uploads/2011/11/Report-on-Patient-Self-Help.pdf
20 Piorkowsky NY.Europe’s hepatitis challenge:defusing the“viral time bomb”.J Hepatol 2009;51:1068-1073[PMID:19854528 DOI:10.1016/j.jhep.2009.09.010]
21 McPherson S,Valappil M,Moses SE,Eltringham G,Miller C,Baxter K,Chan A,Shafiq K,Saeed A,Qureshi R,Hudson M,Bassendine MF.Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England.J Viral Hepat2013;20:638-644[PMID:23910648 DOI:10.1111/jvh.12084]
22 Cohen C,Holmberg SD,McMahon BJ,Block JM,Brosgart CL,Gish RG,London WT,Block TM.Is chronic hepatitis B being undertreated in the United StatesJ Viral Hepat 2011;18:377-383[PMID:21143343 DOI:10.1111/j.13652893.2010.01401.x]
23 Richter C,Beest GT,Sancak I,Aydinly R,Bulbul K,Laetemia-Tomata F,De Leeuw M,Waegemaekers T,Swanink C,Roovers E.Hepatitis B prevalence in the Turkish population of Arnhem:implications for national screening policyEpidemiol Infect 2012;140:724-730[PMID:21740610 DOI:10.1017/S0950268811001270]
24 Meffre C,Le Strat Y,Delarocque-Astagneau E,Dubois F,Antona D,Lemasson JM,Warszawski J,Steinmetz J,Coste D,Meyer JF,Leiser S,Giordanella JP,Gueguen R,Desenclos JC.Prevalence of hepatitis B and hepatitis C virus infections in France in 2004:social factors are important predictors after adjusting for known risk factors.J Med Virol 2010;82:546-555[PMID:20166185 DOI:10.1002/jmv.21734]
25 HahnéSJ,De Melker HE,Kretzschmar M,Mollema L,Van Der Klis FR,Van Der Sande MA,Boot HJ.Prevalence of hepatitis B virus infection in The Netherlands in 1996 and 2007.Epidemiol Infect 2012;140:1469-1480[PMID:22078095 DOI:10 .1017/S095026881100224X]
26 Lin SY,Chang ET,So SK.Stopping a silent killer in the underserved asian and pacific islander community:a chronic hepatitis B and liver cancer prevention clinic by medical students.Asian Pac J Cancer Prev 2009;10:383-386[PMID:19640178]
27 Rossi C,Shrier I,Marshall L,Cnossen S,Schwartzman K,Klein MB,Schwarzer G,Greenaway C.Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees:a systematic review and metaanalysis.PLoS One 2012;7:e44611[PMID:22957088 DOI:10 .1371/journal.pone.0044611]
28 Viral Hepatitis Prevention Board.The clock is running.1997:Deadline for integrating hepatitis B vaccinations into all national immunization programmes,1996(Fact Sheet VHPB/1996/1.Available from:URL:http://hgins.uia.ac.be/esoc/VHPB/vhfs1.html
29 Ganem D,Prince AM.Hepatitis B virus infection--natural history and clinical consequences.N Engl J Med 2004;350:1118-1129[PMID:15014185]
30 Hoofnagle JH,Doo E,Liang TJ,Fleischer R,Lok AS.Management of hepatitis B:summary of a clinical research workshop.Hepatology 2007;45:1056-1075[PMID:17393513]
31 Liaw YF.Prevention and surveillance of hepatitis B virusrelated hepatocellular carcinoma.Semin Liver Dis 2005;25Suppl 1:40-47[PMID:16103980]
32 Lok AS,McMahon BJ.Chronic hepatitis B.Hepatology 2007;45 :507-539[PMID:17256718]
33 Hollinger FB,Liang TJ.Hepatitis B Virus.In:Knipe DM,editor.Fields Virology.4th ed.Philadelphia:Lippincott Williams Wilkins,2001:2971-3036
34 Mahoney FJ,Kane M.Hepatitis B vaccine.In:Plotkin SA,Orenstein WA,editors.Vaccines.3rd ed.Philadelphia:W.B.Saunders Company,1999:158-182
35 Viral Hepatitis Prevention Board.Universal HB immunization by 1997:where are we now1998(Fact Sheet VHPB/1998/2)Available from:URL:http://hgins.uia.ac.be/esoc/VHPB/vhfs2.html
36 Ott JJ,Stevens GA,Groeger J,Wiersma ST.Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity.Vaccine 2012;30:2212-2219[PMID:22273662 DOI:10.1016/j.vaccine.2011.12.116]
37 Hyams KC.Risks of chronicity following acute hepatitis B virus infection:a review.Clin Infect Dis 1995;20:992-1000[PMID:7795104]
38 Custer B,Sullivan SD,Hazlet TK,Iloeje U,Veenstra DL,Kowdley KV.Global epidemiology of hepatitis B virus.J Clin Gastroenterol 2004;38:S158-S168[PMID:15602165 DOI:10 .1097/00004836-200411003-00008]
39 Redd JT,Baumbach J,Kohn W,Nainan O,Khristova M,Williams I.Patient-to-patient transmission of hepatitis B virus associated with oral surgery.J Infect Dis 2007;195:1311-1314[PMID:17397000 DOI:10.1086/513435]
40 Alter MJ.Epidemiology and prevention of hepatitis B.Semin Liver Dis 2003;23:39-46[PMID:12616449 DOI:10.1055/s2003-37583]
41 Van Damme P.Hepatitis B:vaccination programmes in Europe--an update.Vaccine 2001;19:2375-2379[PMID:11257363]
42 Hatzakis A,Wait S,Bruix J,Buti M,Carballo M,Cavaleri M,Colombo M,Delarocque-Astagneau E,Dusheiko G,Esmat G,Esteban R,Goldberg D,Gore C,Lok AS,Manns M,Marcellin P,Papatheodoridis G,Peterle A,Prati D,Piorkowsky N,Rizzetto M,Roudot-Thoraval F,Soriano V,Thomas HC,Thursz M,Valla D,van Damme P,Veldhuijzen IK,Wedemeyer H,Wiessing L,Zanetti AR,Janssen HL.The state of hepatitis B and C in Europe:report from the hepatitis B and C summit conference*.J Viral Hepat 2011;18 Suppl 1:1-16[PMID:21824223 DOI:10.1111/j.1365-2893.2011.01499.x]
43 Duberg AS,Trner A,Davidsdóttir L,Aleman S,Blaxhult A,Svensson A,Hultcrantz R,Bck E,Ekdahl K.Cause of death in individuals with chronic HBV and/or HCV infection,a nationwide community-based register study.J Viral Hepat 2008;15:538-550[PMID:18397223 DOI:10.1111/j.1365-2893.2008.00982.x]
44 García-Fulgueiras A,García-Pina R,Morant C,GarcíaOrtuzar V,Génova R,Alvarez E.Hepatitis C and hepatitis B-related mortality in Spain.Eur J Gastroenterol Hepatol 2009;21:895-901[PMID:19357523 DOI:10.1097/MEG.0b013e328313139d]
45 Marcellin P,Pequignot F,Delarocque-Astagneau E,Zarski JP,Ganne N,Hillon P,Antona D,Bovet M,Mechain M,Asselah T,Desenclos JC,Jougla E.Mortality related to chronic hepatitis B and chronic hepatitis C in France:evidence for the role of HIV coinfection and alcohol consumption.J Hepatol 2008;48:200-207[PMID:18086507]
46 Salleras L,Domínguez A,Bruguera M,Plans P,Espues J,Costa J,Cardeosa N,Plasència A.Seroepidemiology of hepatitis B virus infection in pregnant women in Catalonia(Spain).J Clin Virol 2009;44:329-332[PMID:19230752 DOI:10 .1016/j.jcv.2009.01.002]
47 Zacharakis G,Kotsiou S,Papoutselis M,Vafiadis N,Tzara F,Pouliou E,Maltezos E,Koskinas J,Papoutselis K.Changes in the epidemiology of hepatitis B virus infection following the implementation of immunisation programmes in northeastern Greece.Euro Surveill 2009;14:[PMID:19679032]
48 Fattovich G.Natural history and prognosis of hepatitis B.Semin Liver Dis 2003;23:47-58[PMID:12616450]
49 McMahon BJ.Epidemiology and natural history of hepatitis B.Semin Liver Dis 2005;25 Suppl 1:3-8[PMID:16103976]
50 Hadziyannis SJ,Papatheodoridis GV.Hepatitis B e antigennegative chronic hepatitis B:natural history and treatment.Semin Liver Dis 2006;26:130-141[PMID:16673291]
51 Zarski JP,Marcellin P,Leroy V,Trepo C,Samuel D,GanneCarrie N,Barange K,Canva V,Doffoel M,Cales P.Characteristics of patients with chronic hepatitis B in France:predominant frequency of HBe antigen negative cases.J Hepatol2006;45:355-360[PMID:16750585]
52 Funk ML,Rosenberg DM,Lok AS.World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.J Viral Hepat 2002;9:52 -61[PMID:11851903]
53 Liaw YF,Tai DI,Chu CM,Chen TJ.The development of cirrhosis in patients with chronic type B hepatitis:a prospective study.Hepatology 1998;8:493-496[PMID:3371868]
54 Lin SM,Yu ML,Lee CM,Chien RN,Sheen IS,Chu CM,Liaw YF.Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.J Hepatol 2007;46:45-52[PMID:17107734]
55 Park BK,Park YN,Ahn SH,Lee KS,Chon CY,Moon YM,Park C,Han KH.Long-term outcome of chronic hepatitis B based on histological grade and stage.J Gastroenterol Hepatol2007;22:383-388[PMID:17295771]
56 Wu CF,Yu MW,Lin CL,Liu CJ,Shih WL,Tsai KS,Chen CJ.Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men.Carcinogenesis 2008;29:106-112[PMID:17999990]
57 Chen CF,Lee WC,Yang HI,Chang HC,Jen CL,Iloeje UH,Su J,Hsiao CK,Wang LY,You SL,Lu SN,Chen CJ.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.Gastroenterology2011;141:1240-128,1240-128,[PMID:21703214 DOI:10.1053/j.gastro.2011]
58 Yang HI,Lu SN,Liaw YF,You SL,Sun CA,Wang LY,Hsiao CK,Chen PJ,Chen DS,Chen CJ.Hepatitis B e antigen and the risk of hepatocellular carcinoma.N Engl J Med 2002;347:168 -174[PMID:12124405]
59 Iloeje UH,Yang HI,Su J,Jen CL,You SL,Chen CJ.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.Gastroenterology 2006;130:678-686[PMID:16530509]
60 Chen CJ,Yang HI,Su J,Jen CL,You SL,Lu SN,Huang GT,Iloeje UH.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA2006;295:65-73[PMID:16391218]
61 Chen CL,Yang HI,Yang WS,Liu CJ,Chen PJ,You SL,Wang LY,Sun CA,Lu SN,Chen DS,Chen CJ.Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:a follow-up study in Taiwan.Gastroenterology 2008;135:111-121[PMID:18505690 DOI:10.1053/j.gastro.2008.03.073]
62 Yu MW,Shih WL,Lin CL,Liu CJ,Jian JW,Tsai KS,Chen CJ.Body-mass index and progression of hepatitis B:a population-based cohort study in men.J Clin Oncol 2008;26:5576-5582[PMID:18955457 DOI:10.1200/JCO.2008.16.1075]
63 Young EW,Koch PB,Preston DB.AIDS and homosexuality:a longitudinal study of knowledge and attitude change among rural nurses.Public Health Nurs 1989;6:189-196[PMID:2616450]
64 Fattovich G,Bortolotti F,Donato F.Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors.J Hepatol 2008;48:335-352[PMID:18096267]
65 Fattovich G,Olivari N,Pasino M,D’Onofrio M,Martone E,Donato F.Long-term outcome of chronic hepatitis B in Caucasian patients:mortality after 25 years.Gut 2008;57:84-90[PMID:17715267]
66 Fattovich G,Stroffolini T,Zagni I,Donato F.Hepatocellular carcinoma in cirrhosis:incidence and risk factors.Gastroenterology 2004;127:S35-S50[PMID:15508101]
67 Chen YC,Chu CM,Yeh CT,Liaw YF.Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a long-term follow-up study.Hepatol Int 2007;1:267-273[PMID:19669348]
68 Chu CM,Liaw YF.Hepatitis B virus-related cirrhosis:natural history and treatment.Semin Liver Dis 2006;26:142-152[PMID:16673292]
69 Kappus MR,Sterling RK.Extrahepatic manifestations of acute hepatitis B virus infection.Gastroenterol Hepatol(N Y)2013;9:123-126[PMID:23983659]
70 World Health Organization position paper.Hepatitis B vaccines:Weekly epidemiological record:2009;40:405-420.Available from:URL:http://www.who.int/wer
71 AndréFE.Summary of safety and efficacy data on a yeastderived hepatitis B vaccine.Am J Med 1989;87:14S-20S[PMID:2528292]
72 McMahon BJ,Helminiak C,Wainwright RB,Bulkow L,Trimble BA,Wainwright K.Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons.Am J Med 1992;92:254 -256[PMID:1532114]
73 Update:vaccine side effects,adverse reactions,contraindications,and precautions.Recommendations of the Advisory Committee on Immunization Practices(ACIP)MMWR Recomm Rep 1996;45:1-35[PMID:8801442]
74 Chang MH,Chen CJ,Lai MS,Hsu HM,Wu TC,Kong MS,Liang DC,Shau WY,Chen DS.Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.Taiwan Childhood Hepatoma Study Group.N Engl J Med 1997;336:1855-1859[PMID:9197213]
75 World Health Organization.Available from:URL:http://www.who.int/immunization/hepb_grad_24hours.pdf
76 McMahon BJ,Bulkow LR,Singleton RJ,Williams J,Snowball M,Homan C,Parkinson AJ.Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program.Hepatology 2011;54:801-807[PMID:21618565 DOI:10.1002/hep.24442]
77 Wong VW,Chan HL.Prevention of hepatocellular carcinoma:a concise review of contemporary issues.Ann Hepatol2012;11:284-293[PMID:22481445]
78 Chen DS,Locarnini S,Wait S,Bae SH,Chen PJ,Fung JY,Kim HS,Lu SN,Sung J,Tanaka J,Wakita T,Ward J,Wallace J;CEVHAP North Asia Workshop on Viral Hepatitis.CEVHAP North Asia Workshop on Viral Hepatitis.Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia.J Hepatol 2013;59:1073-1080[PMID:23850942 DOI:10 .1016/j.jhep.2013.06.029]
79 Lee MS,Kim DH,Kim H,Lee HS,Kim CY,Park TS,Yoo KY,Park BJ,Ahn YO.Hepatitis B vaccination and reduced risk of primary liver cancer among male adults:a cohort study in Korea.Int J Epidemiol 1998;27:316-319[PMID:9602416]
80 Blumberg BS.Primary and secondary prevention of liver cancer caused by HBV.Front Biosci(Schol Ed)2010;2:756 -763[PMID:20036981]
81 Quoilin S,Hutse V,Vandenberghe H,Claeys F,Verhaegen E,De Cock L,Van Loock F,Top G,Van Damme P,Vranckx R,Van Oyen H.A population-based prevalence study of hepatitis A,B and C virus using oral fluid in Flanders,Belgium.Eur J Epidemiol 2007;22:195-202[PMID:17356926]
82 Nardone A,Anastassopoulou CG,Theeten H,Kriz B,Davidkin I,Thierfelder W,O’Flanagan D,Bruzzone B,Mossong J,Boot HJ,Butur D,SlacikováM,Panait ML,Hellenbrand W,DE Melker H,SobotováZ,Icardi G,Andrews N,Pebody RG,VAN Damme P,Kafatos G,Miller E,Hatzakis A.A comparison of hepatitis B seroepidemiology in ten European countries.Epidemiol Infect 2009;137:961-969[PMID:19102797DOI:10.1017/S0950268808001672]
83 Czarkowski MP,Bobel D.[Hepatitis B in Poland in 2006].Przegl Epidemiol 2008;62:317-324[PMID:18807474]
84 Czarkowski MP,Rosińska M.[Hepatitis B in Poland in2005].Przegl Epidemiol 2007;61:273-279[PMID:17956042]
85 Pitigoi D,Rafila A,Pistol A,Arama V,Molagic V,StreinuCercel A.Trends in hepatitis B incidence in Romania,1989-2005.Euro Surveill 2008;13:[PMID:18445385]
86 Papaevangelou V,Hadjichristodoulou C,Cassimos DC,Pantelaki K,Tzivaras A,Hatzimichael A,Theodoridou M.Seroepidemiology of hepatitis B in Greek children 6years after the implementation of universal vaccination.Infection 2008;36:135-139[PMID:18231718 DOI:10.1007/s15010-007-7096-6]
87 Fabris P,Baldo V,Baldovin T,Bellotto E,Rassu M,Trivello R,Tramarin A,Tositti G,Floreani A.Changing epidemiology of HCV and HBV infections in Northern Italy:a survey in the general population.J Clin Gastroenterol 2008;42:527-532[PMID:18277889 DOI:10.1097/MCG.0b013e318030e3ab]
88 Baaten GG,Sonder GJ,Dukers NH,Coutinho RA,Van den Hoek JA.Population-based study on the seroprevalence of hepatitis A,B,and C virus infection in Amsterdam,2004.J Med Virol 2007;79:1802-1810[PMID:17935187]
89 Voiculescu M,Iliescu L,Ionescu C,Micu L,Ismail G,Zilisteanu D,Radasan A,Micu G,Pertache I.A cross-sectional epidemiological study of HBV,HCV,HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania.J Gastrointestin Liver Dis 2010;19:43-48[PMID:20361074]
90 Salleras L,Domínguez A,Bruguera M,Plans P,Costa J,Cardeosa N,Batalla J,Plasència A.Declining prevalence of hepatitis B virus infection in Catalonia(Spain)12 years after the introduction of universal vaccination.Vaccine 2007;25:8726-8731[PMID:18045753]
91 Sorrell MF,Belongia EA,Costa J,Gareen IF,Grem JL,Inadomi JM,Kern ER,McHugh JA,Petersen GM,Rein MF,Strader DB,Trotter HT.National Institutes of Health Consensus Development Conference Statement:management of hepatitis B.Ann Intern Med 2009;150:104-110[PMID:19124811]
92 Weinbaum CM,Williams I,Mast EE,Wang SA,Finelli L,Wasley A,Neitzel SM,Ward JW.Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.MMWR Recomm Rep 2008;57 :1-20[PMID:18802412]
93 Gastroenterological Society of Australia and Digestive Health Foundation.Australian and New Zealand chronic hepatitis B(CHB)recommendations.Clinical update[webpage on the Internet].Victoria,Australia:The Digestive Health Foundation;2010.Available from:URL:http://www.gesa.org.au/files/editor_upload/File/Professional/CHB.pdf
94 Kowdley KV,Wang CC,Welch S,Roberts H,Brosgart CL.Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin.Hepatology 2012;56:422-433[PMID:22105832 DOI:10.1002/hep.24804]
95 Wilson JM,Jungner G.Principles and practice of screening for disease.Geneva,Switzerland:World Health Organization,1968
96 Almy TP.Our“amber waves of grain”.Hosp Pract 1976;11:11 ,16[PMID:1017829]
97 Hutton DW,Tan D,So SK,Brandeau ML.Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.Ann Intern Med 2007;147:460-469[PMID:17909207]
98 Veldhuijzen IK,Toy M,HahnéSJ,De Wit GA,Schalm SW,de Man RA,Richardus JH.Screening and early treatment of migrants for chronic hepatitis B virus infection is costeffective.Gastroenterology 2010;138:522-530[PMID:19879275DOI:10.1053/j.gastro.2009.10.039]
99 Rein DB,Lesesne SB,Smith BD,Weinbaum CM.Models of community-based hepatitis B surface antigen screening programs in the U.S.and their estimated outcomes and costs.Public Health Rep 2011;126:560-567[PMID:21800750]
100 Wong WW,Woo G,Jenny Heathcote E,Krahn M.Cost effectiveness of screening immigrants for hepatitis B.Liver Int 2011;31:1179-1190[PMID:21745300 DOI:10.1111/j.1478-3231.2011.02559.x]
101 Canadian Agency for Drugs and Technologies in Health.Common Drug Review Drug Database.Ottawa,ON,Canada:Canadian Agency for Drugs and Technologies in Health,2009.Available from:URL:http://www.cadth.ca/en/products/cde
102 Fischer C,Mauss S,Zehnter E,Bokemeyer B,Heyne R,Hüppe D.[Epidemiology and clinical characteristics of patients with chronic hepatitis B(CHB)in Germany-results of a nationwide cross-sectional study].Z Gastroenterol 2012;50:22 -29[PMID:22222794 DOI:10.1055/s-0031-1281628]
103 Niederau C,Heintges T,Niederau M,Stremmel W,Strohmeyer G.[How many patients with chronic viral hepatitis qualify for interferon therapyProspective analysis of university ambulatory care].Med Klin(Munich)1993;88:511-55,562 [PMID:8232088]
104 Cornberg M,Protzer U,Petersen J,Wedemeyer H,Berg T,Jilg W,Erhardt A,Wirth S,Sarrazin C,Dollinger MM,Schirmacher P,Dathe K,Kopp IB,Zeuzem S,Gerlich WH,Manns MP.[Prophylaxis,diagnosis and therapy of hepatitis B virus infection-the German guideline].Z Gastroenterol 2011;49:871-930[PMID:21748700 DOI:10.1055/s-0031-1273462]
105 Sarrazin C,Berg T,Ross RS,Schirmacher P,Wedemeyer H,Neumann U,Schmidt HH,Spengler U,Wirth S,Kessler HH,Peck-Radosavljevic M,Ferenci P,Vogel W,Moradpour D,Heim M,Cornberg M,Protzer U,Manns MP,Fleig WE,Dollinger MM,Zeuzem S.[Prophylaxis,diagnosis and therapy of hepatitis C virus(HCV)infection:the German guidelines on the management of HCV infection].Z Gastroenterol 2010;48:289 -351[PMID:20119896 DOI:10.1055/s-0028-1110008]
106 Tozun N,Ozdogan OC,Cakaloglu Y,Idilman R,Karasu Z,Akarca US.A Nationwide Prevalence Study and Risk Factors for Hepatitis A,B,C and D Infections in Turkey.Boston:AASLD National Meeting in Boston,2010:A789
107 Contini C,Badia L,Cultrera R,Grilli A,De Togni A.Epidemiological,clinical and laboratory features of chronic hepatitis B infection in a cohort of immigrant and Italian patients from Ferrara,Italy.Ann Hepatol 2012;11:862-869[PMID:23109449]
108 Levi M,Bonanni P,Falla A,Veldhuijzen I.Awareness of hepatitis B and C screening and patients management guidelines among health care professionals in six eurpean countries.Annual Meeting of the European Association for the Study of the Liver,Amsterdam 2013.J Hepatol 2013;58:A2568
109 Falla A,Veldhuijzen I,Ahmad A,Levi M,Richardus JH.Chronic hepatitis B and C management and treatment restrictions-current practice in 6 european countries.Annual Meeting of the European Association for the Study of the Liver,Amsterdam 2013.J Hepatol 2013;58:A2479
110 Vermehren J,Schlosser B,Domke D,Elanjimattom S,Müller C,Hintereder G,Hensel-Wiegel K,Tauber R,Berger A,Haas N,Walcher F,Mckel M,Lehmann R,Zeuzem S,Sarrazin C,Berg T.High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany:a prospective screening analysis of 28,809 patients.PLoS One 2012;7:e41206[PMID:22848445 DOI:10.1371/journal.pone.0041206]
111 Buggisch P,Petersen J,Urlea-Schn I.High prevalence of chronic hepatitis C in 8009 patients with migration background living in Germany.Meeting of the AASLD 2012 in Boston.Hepatology 2012;56:A768
112 Niederau C,Zehnter E,Kapagiannidis C.Werden die Empfehlungen des Robert-Koch-Instituts(RKI)zur Diagnose der Hepatitis C im hausrztlichen Bereich umgesetztEine prospektive Untersuchung von 192 Hausarztpraxen in Deutschland.Z Gastroenterol 2006;44:A320
113 Rossol S,Bartel J.[Chronic hepatitis C virus infection].MMW Fortschr Med 2006;148:36-37[PMID:17619422]
114 Wedemeyer H,Hofmann WP,Lueth S,Malinski P,Thimme R,Tacke F,Wiegand J.[ALT screening for chronic liver diseases:scrutinizing the evidence].Z Gastroenterol 2010;48:46 -55[PMID:20072996 DOI:10.1055/s-00281109980]
115 Kunkel J,Ahmad A,Levi M,Reintjes R,Veldhuijzen,Foster G.Screening for viral hepatitis among migrants in the EUThe quest for“good screening practice”.Annual Meeting of the European Association for the Study of the Liver,Amsterdam 2013.J Hepatol 2013;58:A2281
116 van der Veen YJ,de Zwart O,Voeten HA,Mackenbach JP,Richardus JH.Hepatitis B screening in the Turkish-Dutch population in Rotterdam,the Netherlands;qualitative assessment of socio-cultural determinants.BMC Public Health2009;9:328[PMID:19740421 DOI:10.1186/1471-2458-9-328]
117 Malespin M,Wong S,Siqueira F,Luc B,Ravaee B,Vainder C,Cotler SJ.Barriers to treatment of hepatitis B in an urban Chinatown community.J Clin Gastroenterol 2012;46:e66-e70[PMID:22460162 DOI:10.1097/MCG.0b013e31824e159c]
118 RRobotin M,Patton Y,George J.Getting it right:the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers.Int J Gen Med 2013:6 115-122[PMID:23662074 DOI:10.2147/IJGM.S41299]
119 HahnéSJ,Veldhuijzen IK,Wiessing L,Lim TA,Salminen M,Laar Mv.Infection with hepatitis B and C virus in Europe:a systematic review of prevalence and cost-effectiveness of screening.BMC Infect Dis 2013;13:181[PMID:23597411DOI:10.1186/1471-2334-13-181]
120 Dulay M,Zola J,Hwang J,Baron A,Lai C.Are primary care clinicians knowledgeable about screening for chronic hepatitis B infectionJ Gen Intern Med 2007;22:747-753
121 Lai CJ,Nguyen TT,Hwang J,Stewart SL,Kwan A,McPhee SJ.Provider knowledge and practice regarding hepatitis B screening in Chinese-speaking patients.J Cancer Educ 2007;22 :37-41[PMID:17570807]
122 Tormans G,Van Damme P,Carrin G,Clara R,Eylenbosch W.Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium.Soc Sci Med 1993;37:173-181[PMID:8351532]
123 Jordan R,Law M.An appraisal of the efficacy and cost effectiveness of antenatal screening for hepatitis B.J Med Screen1997;4:117-127[PMID:9368867]
124 Dwyer MJ,McIntyre PG.Ante-natal screening for hepatitis B surface antigen:an appraisal of its value in a low prevalence area.Epidemiol Infect 1996;117:121-131[PMID:8760959]
125 Audet AM,Delage G,Remis RS.Screening for HBsAg in pregnant women:a cost analysis of the universal screening policy in the province of Quebec.Can J Public Health 1991;82:191 -195[PMID:1909210]
126 Thomas IL.Cost effectiveness of antenatal hepatitis B screening and vaccination of infants.Aust N Z J Obstet Gynaecol 1990;30:331-335[PMID:2150586]
127 Eckman MH,Kaiser TE,Sherman KE.The cost-effectiveness of screening for chronic hepatitis B infection in the United States.Clin Infect Dis 2011;52:1294-1306[PMID:21540206DOI:10.1093/cid/cir199]
128 Williams R,Holt AP.Screening immigrants for tuberculosis--why not for HBV infectionLancet 2013;381:2164-2165[PMID:23791343 DOI:10.1016/S0140-6736(13)61438-5]
129 Pendleton S,Wilson-Webb P.Rising curve:chronic hepatitis B infection in the UK.Available from:URL:http://www.hepb.org.uk/information/resources/rising_curve_chronic_hepatitis_b_infection_in_the_uk/risin g_curve.pdf
130 Tedder RS,Rodger AJ,Fries L,Ijaz S,Thursz M,Rosenberg W,Naoumov N,Banatvala J,Williams R,Dusheiko G,Chokshi S,Wong T,Rosenberg G,Moreea S,Bassendine M,Jacobs M,Mills PR,Mutimer D,Ryder SD,Bathgate A,Hussaini H,Dillon JF,Wright M,Bird G,Collier J,Anderson M,Johnson AM.The diversity and management of chronic hepatitis B virus infections in the United Kingdom:a wake-up call.Clin Infect Dis 2013;56:951-960[PMID:23223601 DOI:10.1093/cid/cis1013]
131 Beutels M,Van Damme P,Aelvoet W,Desmyter J,Dondeyne F,Goilav C,Mak R,Muylle L,Pierard D,Stroobant A,Van Loock F,Waumans P,Vranckx R.Prevalence of hepatitis A,B and C in the Flemish population.Eur J Epidemiol 1997;13:275-280[PMID:9258525]
132 Roudot-Thoraval F,Kouadja F,Wirquin V,Thiers V,Avons P,Brechot C,Dhumeaux D.[Prevalence of HBs antigen carriers and markers of B virus replication in a population of pregnant women,in France].Gastroenterol Clin Biol 1989;13:353 -356[PMID:2737390]
133 Vall Mayans M,Arellano E,Armengol P,EscribàJM,Loureiro E,SaladiéP,Sanz B,Saravanya M,Vall M,Villena MJ.[HIV infection and other sexually-transmitted infections among immigrants in Barcelona].Enferm Infecc Microbiol Clin2002;20:154-156[PMID:11996700]
134 Panagopoulos P,Economou A,Kasimi A,Spyropoulou P,Kanellopoulos N,Dadiotis L,Salamalekis E.Prevalence of hepatitis B and C in the maternity department of a Greek district hospital.J Matern Fetal Neonatal Med 2004;16:106-110[PMID:15512720]
135 Stroffolini T,Bianco E,Szklo A,Bernacchia R,Bove C,Colucci M,Cristina Coppola R,D’Argenio P,Lopalco P,Parlato A,Ragni P,Simonetti A,Zotti C,Mele A.Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy.Vaccine 2003;21:1246-1249[PMID:12559805]
136 France AM,Bornschlegel K,Lazaroff J,Kennedy J,Balter S.Estimating the prevalence of chronic hepatitis B virus infection--New York City,2008.J Urban Health 2012;89:373-383[PMID:22246675 DOI:10.1007/s11524011-9653-7]
137 Connolly MA,Gayer M,Ryan MJ,Salama P,Spiegel P,Heymann DL.Communicable diseases in complex emergencies:impact and challenges.Lancet 2004;364:1974-1983[PMID:15567014]
138 Gayer M,Legros D,Formenty P,Connolly MA.Conflict and emerging infectious diseases.Emerg Infect Dis 2007;13:1625-1631[PMID:18217543]
139 European Centre for Disease Control and Prevention(2010).Hepatitis B and C in the EU neighbourhood:prevalence,burden of disease and screening policies.Available from:URL:http://ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C_EU_neighbourhood.pdf
140 McDermott S,Desmeules M,Lewis R,Gold J,Payne J,Lafrance B,Vissandjée B,Kliewer E,Mao Y.Cancer incidence among Canadian immigrants,1980-1998:results from a national cohort study.J Immigr Minor Health 2011;13:15-26[PMID:20490685 DOI:10.1007/s10903-010-9347-3]
141 DesMeules M,Gold J,McDermott S,Cao Z,Payne J,Lafrance B,Vissandjée B,Kliewer E,Mao Y.Disparities in mortality patterns among Canadian immigrants and refugees,1980-1998:results of a national cohort study.J Immigr Health 2005;7:221-232[PMID:19813288]
142 Rein DB,Lesesne SB,Leese PJ,Weinbaum CM.Communitybased hepatitis B screening programs in the United States in 2008.J Viral Hepat 2010;17:28-33[PMID:19674286 DOI:10 .1111/j.1365-2893.2009.01165.x]
143 IOM(Institute of Medicine).2010.Hepatitis and Liver Cancer:A National Strategy for Prevention and Control of Hepatitis B and C.Washington,DC:The National Academies Press.Available from:URL:http://www.nap.edu/catalog/12793.html
144 Chironna M,Germinario C,Lopalco PL,Carrozzini F,Barbuti S,Quarto M.Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey.Infection 2003;31 :70-74[PMID:12682810]
145 Michos A,Terzidis A,Kalampoki V,Pantelakis K,Spanos T,Petridou ET.Seroprevalence and risk factors for hepatitis A,B,and C among Roma and non-Roma children in a deprived area of Athens,Greece.J Med Virol 2008;80:791-797[PMID:18360892]
146 Roussos A,Goritsas C,Pappas T,Spanaki M,Papadaki P,Ferti A.Prevalence of hepatitis B and C markers among refugees in Athens.World J Gastroenterol 2003;9:993-995[PMID:12717844]
147 Burnazian AI.[Japanese public health system in Southern Sakhalin in 1945(on the 30th anniversary of the victory over Japanese imperialism)].Sov Zdravookhr 1975;(10):63-67[PMID:1105797]
148 Palumbo E,Scotto G,Faleo G,Cibelli DC,Angarano G.Prevalence of HBV genotypes in South American immigrants affected by HBV-related chronic active hepatitis.Braz J Infect Dis 2007;11:311-313[PMID:17684630]
149 Palumbo E,Scotto G,Faleo G,Cibelli DC,Saracino A,Angarano G.Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis.Arq Gastroenterol2007;44:54-57[PMID:17639184]
150 Majori S,Baldo V,Tommasi I,Malizia M,Floreani A,Monteiro G,Ferrari A,Accordini A,Guzzo P,Baldovin T.Hepatitis A,B,and C infection in a community of sub-Saharan immigrants living in Verona(Italy).J Travel Med 2008;15:323-327[PMID:19006505 DOI:10.1111/j.1708-8305.2008.00230.x]
151 Palumbo E,Scotto G,Cibelli DC,Faleo G,Saracin A,Angarano G.Immigration and hepatitis B virus:epidemiological,clinical and therapeutic aspects.East Mediterr Health J 2008;14 :784-790[PMID:19166160]
152 Manzardo C,Trevio B,Gómez i Prat J,Cabezos J,MonguíE,Clavería I,Luis Del Val J,Zabaleta E,Zarzuela F,Navarro R.Communicable diseases in the immigrant population attended to in a tropical medicine unit:epidemiological aspects and public health issues.Travel Med Infect Dis 2008;6:4 -11[PMID:18342267 DOI:10.1016/j.tmaid.2007.11.002]
153 Aweis D,Brabin BJ,Beeching NJ,Bunn JE,Cooper C,Gardner K,Iriyagolle C,Hart CA.Hepatitis B prevalence and risk factors for HBsAg carriage amongst Somali households in Liverpool.Commun Dis Public Health 2001;4:247-252[PMID:12109390]
154 Chironna M,Germinario C,Lopalco PL,Carrozzini F,Quarto M.Prevalence of hepatitis virus infections in Kosovar refugees.Int J Infect Dis 2001;5:209-213[PMID:11953219]
155 Veldhuijzen IK,van Driel HF,Vos D,de Zwart O,van Doornum GJ,de Man RA,Richardus JH.Viral hepatitis in a multi-ethnic neighborhood in the Netherlands:results of a community-based study in a low prevalence country.Int J Infect Dis 2009;13:e9-e13[PMID:18678518 DOI:10.1016/j.ijid.2008.05]
156 Cowan SA,Bagdonaite J,Qureshi K.Universal hepatitis B screening of pregnant women in Denmark ascertains substantial additional infections:results from the first five months.Euro Surveill 2006;11:E060608.3[PMID:16819119]
157 Keane FE,Neale J,Phillips T,Heard L,Jones R,Guttridge B,Bendall R.Offering routine antenatal testing for HIV and hepatitis B in the rural setting of Cornwall.Sex Transm Infect2002;78:133-134[PMID:12081176]
158 Universal antenatal screening for hepatitis B and immunisation of babies at risk.Commun Dis Rep CDR Wkly 1998;8:281,284 [PMID:9745169]
159 Stroffolini T,Pasquini P.Five years of vaccination campaign against hepatitis B in Italy in infants of hepatitis B surface antigen carrier mothers.Ital J Gastroenterol 1990;22:195-197[PMID:2131945]
160 Loubière S,Rotily M,Moatti JP.Prevention could be less cost-effective than cure:the case of hepatitis C screening policies in France.Int J Technol Assess Health Care 2003;19:632 -645[PMID:15095769]
161 Papaevangelou V,Hadjichristodoulou C,Cassimos D,Theodoridou M.Adherence to the screening program for HBV infection in pregnant women delivering in Greece.BMC Infect Dis 2006;6:84[PMID:16681862]
162 Adamo B,Stroffolini T,Sagliocca L,Simonetti A,Iadanza F,Fossi E,Tancredi F,Mele A.Ad hoc survey of hepatitis B vaccination campaign in newborns of HBsAg positive mothers and in 12-year-old subjects in southern Italy.Vaccine1998;16:775-777[PMID:9627934]
163 Bonura F,Sorgi M,Perna AM,Puccio G,Tramuto F,Cajozzo C,Romano N,Vitale F.Pregnant women as a sentinel population to target and implement hepatitis B virus(HBV)vaccine coverage:a three-year survey in Palermo,Sicily.Vaccine2005;23:3243-3246[PMID:15837228]
164 Beckers K,Schaad UB,Heininger U.Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns.Eur J Pediatr 2004;163:654-657[PMID:15316775]
165 van Steenbergen JE,Leentvaar-Kuijpers A,Baayen D,Dukers HT,van Doornum GJ,van den Hoek JA,Coutinho RA.Evaluation of the hepatitis B antenatal screening and neonatal immunization program in Amsterdam,1993-1998.Vaccine2001;20:7-11[PMID:11567738]
166 Bracebridge S,Irwin D,Millership S.Prevention of perinatal hepatitis B transmission in a health authority area:an audit.Commun Dis Public Health 2004;7:138-141[PMID:15259417]
167 Lauer GM,Walker BD.Hepatitis C virus infection.N Engl J Med 2001;345:41-52[PMID:11439948]
168 van der Poel CL,Janssen MP,Borkent-Raven B.The collection,testing and use of blood and blood products in Europe in 2005.Europe:Final Report for the Council of Europe,2009
169 Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection,testing,processing,storage and distribution of human blood and blood components and amending Directive 2001/83/EC.Europa:Summaries of EU legislation,2002
170 Winstock AR,Sheridan J,Lovell S,Farrell M,Strang J.National survey of hepatitis testing and vaccination services provided by drug services in England and Wales.Eur J Clin Microbiol Infect Dis 2000;19:823-828[PMID:11152306]
171 van Steenbergen JE.Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands(1998-2000)among men who have sex with men,hard drug users,sex workers and heterosexual persons with multiple partners.J Hepatol 2002;37:507-513[PMID:12217605]
172 Centers for Disease Control and Prevention(CDC).Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students.MMWR Recomm Rep 2012;61:1-12[PMID:22763928]
173 Tillmann HL,Zachou K,Dalekos GN.Management of severe acute to fulminant hepatitis B:to treat or not to treat or when to treatLiver Int 2012;32:544-553[PMID:22099371DOI:10.1111/j.1478-3231.2011.02682.x]
174 Fattovich G,Giustina G,Sanchez-Tapias J,Quero C,Mas A,Olivotto PG,Solinas A,Almasio P,Hadziyannis S,Degos F,de Moura MC,Krogsgaard K,Pantalena M,Realdi G,Corrocher R,Schalm SW.Delayed clearance of serum HBsAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis.European Concerted Action on Viral Hepatitis(EUROHEP)Am J Gastroenterol 1998;93:896-900[PMID:9647014]
175 Perrillo R,Hou J,Papatheodoridis G,Manns M.Patient management and clinical decision making in HBV--aims of therapy and what we can achieve.Antivir Ther 2010;15Suppl 3:45-51[PMID:21041903 DOI:10.3851/IMP1623]
176 Li WC,Wang MR,Kong LB,Ren WG,Zhang YG,Nan YM.Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion:a metaanalysis of controlled clinical trials.BMC Infect Dis 2011;11:165 [PMID:21651820 DOI:10.1186/1471-2334-11-165]
177 Niederau C,Heintges T,Lange S,Goldmann G,Niederau CM,Mohr L,Hussinger D.Long-term follow-up of HBeAgpositive patients treated with interferon alfa for chronic hepatitis B.N Engl J Med 1996;334:1422-1427[PMID:8618580]
178 Brunetto MR,Oliveri F,Coco B,Leandro G,Colombatto P,Gorin JM,Bonino F.Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients:a long term cohort study.J Hepatol 2002;36:263-270[PMID:11830339]
179 Chu CJ,Hussain M,Lok AS.Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection.Hepatology 2002;36:1408-1415[PMID:12447866]
180 Lai M,Hyatt BJ,Nasser I,Curry M,Afdhal NH.The clinical significance of persistently normal ALT in chronic hepatitis B infection.J Hepatol 2007;47:760-767[PMID:17928090]
181 Chu CM,Liaw YF.Chronic hepatitis B virus infection acquired in childhood:special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.J Viral Hepat 2007;14:147-152[PMID:17305879]
182 Liaw YF,Chu CM,Su IJ,Huang MJ,Lin DY,Chang-Chien CS.Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.Gastroenterology 1983;84:216-219[PMID:6848402]
183 Lok AS,Lai CL,Wu PC,Leung EK,Lam TS.Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection.Gastroenterology 1987;92:1839-1843[PMID:3569757]
184 Lok AS,Lai CL.Acute exacerbations in Chinese patients with chronic hepatitis B virus(HBV)infection.Incidence,predisposing factors and etiology.J Hepatol 1990;10:29-34[PMID:2307827]
185 Liaw YF,Tai DI,Chu CM,Pao CC,Chen TJ.Acute exacerbation in chronic type B hepatitis:comparison between HBeAg and antibody-positive patients.Hepatology 1987;7:20-23[PMID:2433203]
186 Han KH,Kim DY.Chronic HBV infection with persistently normal ALT:not to treat.Hepatol Int 2008;2:185-189[DOI:10 .1007/s12072-008-9068-z]
187 Papatheodoridis GV,Manolakopoulos S,Liaw YF,Lok A.Follow-up and indications for liver biopsy in HBeAgnegative chronic hepatitis B virus infection with persistently normal ALT:a systematic review.J Hepatol 2012;57:196-202[PMID:22450396 DOI:10.1016/j.jhep.2011.11.030]
188 Wong GL,Wong VW,Choi PC,Chan AW,Chan HL.Development of a non-invasive algorithm with transient elastography(Fibroscan)and serum test formula for advanced liver fibrosis in chronic hepatitis B.Aliment Pharmacol Ther 2010;31:1095-1103[PMID:20180785 DOI:10.1111/j.13652036.2010.04276.x]
189 Fung J,Lai CL,Seto WK,Yuen MF.The use of transient elastography in the management of chronic hepatitis B.Hepatol Int 2011;Epub ahead of print[PMID:21695588]
190 Shim JH,Lee HC,Kim KM,Lim YS,Chung YH,Lee YS,Suh DJ.Efficacy of entecavir in treatment-nave patients with hepatitis B virus-related decompensated cirrhosis.J Hepatol 2010;52:176-182[PMID:20006394 DOI:10.1016/j.jhep.2009.11.007]
191 Liaw YF,Raptopoulou-Gigi M,Cheinquer H,Sarin SK,Tanwandee T,Leung N,Peng CY,Myers RP,Brown RS,Jeffers L,Tsai N,Bialkowska J,Tang S,Beebe S,Cooney E.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation:a randomized,openlabel study.Hepatology 2011;54:91-100[PMID:21503940DOI:10.1002/hep.24361]
192 Reijnders JG,Perquin MJ,Zhang N,Hansen BE,Janssen HL.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.Gastroenterology 2010;139:491-498[PMID:20381492DOI:10.1053/j.gastro.2010.03.059]
193 van Nunen AB,Hansen BE,Suh DJ,Lhr HF,Chemello L,Fontaine H,Heathcote J,Song BC,Janssen HL,de Man RA,Schalm SW.Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.Gut 2003;52:420-424[PMID:12584227]
194 Lee HW,Lee HJ,Hwang JS,Sohn JH,Jang JY,Han KJ,Park JY,Kim do Y,Ahn SH,Paik YH,Lee CK,Lee KS,Chon CY,Han KH.Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.Hepatology 2010;51:415-421[PMID:19902424 DOI:10.1002/hep.23323]
195 Song BC,Suh DJ,Lee HC,Chung YH,Lee YS.Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.Hepatology2000;32:803-806[PMID:11003626]
196 Dienstag JL,Cianciara J,Karayalcin S,Kowdley KV,Willems B,Plisek S,Woessner M,Gardner S,Schiff E.Durability of serologic response after lamivudine treatment of chronic hepatitis B.Hepatology 2003;37:748-755[PMID:12668966]
197 Yoon SK,Jang JW,Kim CW,Bae SH,Choi JY,Choi SW,Lee YS,Lee CD,Chung KW,Sun HS,Kim BS.Long-term results of lamivudine monotherapy in Korean patients with HBeAgpositive chronic hepatitis B:response and relapse rates,and factors related to durability of HBeAg seroconversion.Intervirology 2005;48:341-349[PMID:16024938]
198 Wu IC,Shiffman ML,Tong MJ,Marcellin P,Mondou E,Lok D,Trihn HN,Carosi G,Akarca US,Gadano A,Habersetzer F.Entecavir(ETV)monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir(TDF)in nucleos(t)ide naive patients with chronic hepatitis B:the BELOW study.Hepatology 2011;54:471A
199 Cooksley WG,Piratvisuth T,Lee SD,Mahachai V,Chao YC,Tanwandee T,Chutaputti A,Chang WY,Zahm FE,Pluck N.Peginterferon alpha-2a(40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat 2003;10:298-305[PMID:12823597]
200 Zhao H,Kurbanov F,Wan MB,Yin YK,Niu JQ,Hou JL,Wei L,Wang GQ,Tanaka Y,Mizokami M,Si CW.Genotype B and younger patient age associated with better response to low-dose therapy:a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.Clin Infect Dis 2007;44:541 -548[PMID:17243057]
201 Chan HL,Leung NW,Hui AY,Wong VW,Liew CT,Chim AM,Chan FK,Hung LC,Lee YT,Tam JS,Lam CW,Sung JJ.A randomized,controlled trial of combination therapy for chronic hepatitis B:comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.Ann Intern Med2005;142:240-250[PMID:15710957]
202 Cao ZH,Ma LN,Zhang HW,Liu YL,Chen XY.Extended treatment with peginterferonα-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.J Dig Dis 2013;14:446-450[PMID:23615131 DOI:10.1111/1751-2980.12065]
203 Buster EH,Flink HJ,Cakaloglu Y,Simon K,Trojan J,Tabak F,So TM,Feinman SV,Mach T,Akarca US,Schutten M,Tielemans W,van Vuuren AJ,Hansen BE,Janssen HL.Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2 b.Gastroenterology 2008;135:459-467[PMID:18585385 DOI:10 .1053/j.gastro.2008.05.031]
204 Wong VW,Wong GL,Yan KK,Chim AM,Chan HY,Tse CH,Choi PC,Chan AW,Sung JJ,Chan HL.Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.Hepatology 2010;51:1945-1953[PMID:20209602 DOI:10.1002/hep.23568]
205 Liaw YF,Sheen IS,Lee CM,Akarca US,Papatheodoridis GV,Suet-Hing Wong F,Chang TT,Horban A,Wang C,Kwan P,Buti M,Prieto M,Berg T,Kitrinos K,Peschell K,Mondou E,Frederick D,Rousseau F,Schiff ER.Tenofovir disoproxil fumarate(TDF),emtricitabine/TDF,and entecavir in patients with decompensated chronic hepatitis B liver disease.Hepatology 2011;53:62-72[PMID:21254162 DOI:10.1002/hep.23952]
206 Lau GK,Piratvisuth T,Luo KX,Marcellin P,Thongsawat S,Cooksley G,Gane E,Fried MW,Chow WC,Paik SW,Chang WY,Berg T,Flisiak R,McCloud P,Pluck N.Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med 2005;352:2682-2695[PMID:15987917]
207 Janssen HL,van Zonneveld M,Senturk H,Zeuzem S,Akarca US,Cakaloglu Y,Simon C,So TM,Gerken G,de Man RA,Niesters HG,Zondervan P,Hansen B,Schalm SW.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial.Lancet 2005;365:123-129[PMID:15639293]
208 Lai CL,Chien RN,Leung NW,Chang TT,Guan R,Tai DI,Ng KY,Wu PC,Dent JC,Barber J,Stephenson SL,Gray DF.A one-year trial of lamivudine for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group.N Engl J Med 1998;339:61 -68[PMID:9654535]
209 Dienstag JL,Schiff ER,Wright TL,Perrillo RP,Hann HW,Goodman Z,Crowther L,Condreay LD,Woessner M,Rubin M,Brown NA.Lamivudine as initial treatment for chronic hepatitis B in the United States.N Engl J Med 1999;341:1256-1263[PMID:10528035]
210 Chang TT,Gish RG,de Man R,Gadano A,Sollano J,Chao YC,Lok AS,Han KH,Goodman Z,Zhu J,Cross A,DeHertogh D,Wilber R,Colonno R,Apelian D;BEHoLD AI463022 Study Group.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med2006;354:1001-1010[PMID:16525137]
211 Lai CL,Gane E,Liaw YF,Hsu CW,Thongsawat S,Wang Y,Chen Y,Heathcote EJ,Rasenack J,Bzowej N,Naoumov NV,Di Bisceglie AM,Zeuzem S,Moon YM,Goodman Z,Chao G,Constance BF,Brown NA;Globe Study Group.Telbivudine versus lamivudine in patients with chronic hepatitis B.N Engl J Med 2007;357:2576-2588[PMID:18094378]
212 Marcellin P,Chang TT,Lim SG,Tong MJ,Sievert W,Shiffman ML,Jeffers L,Goodman Z,Wulfsohn MS,Xiong S,Fry J,Brosgart CL.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med 2003;348 :808-816[PMID:12606735]
213 Marcellin P,Heathcote EJ,Buti M,Gane E,de Man RA,Krastev Z,Germanidis G,Lee SS,Flisiak R,Kaita K,Manns M,Kotzev I,Tchernev K,Buggisch P,Weilert F,Kurdas OO,Shiffman ML,Trinh H,Washington MK,Sorbel J,Anderson J,Snow-Lampart A,Mondou E,Quinn J,Rousseau F.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.N Engl J Med 2008;359:2442-2455[PMID:19052126]
214 Liaw YF,Jia JD,Chan HL,Han KH,Tanwandee T,Chuang WL,Tan DM,Chen XY,Gane E,Piratvisuth T,Chen L,Xie Q,Sung JJ,Wat C,Bernaards C,Cui Y,Marcellin P.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.Hepatology 2011;54 :1591-1599[PMID:22045673 DOI:10.1002/hep.24555]
215 van Zonneveld M,Honkoop P,Hansen BE,Niesters HG,Darwish Murad S,de Man RA,Schalm SW,Janssen HL.Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.Hepatology 2004;39:804-810[PMID:14999700]
216 Liaw YF,Leung NW,Chang TT,Guan R,Tai DI,Ng KY,Chien RN,Dent J,Roman L,Edmundson S,Lai CL.Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.Asia Hepatitis Lamivudine Study Group.Gastroenterology 2000;119:172-180[PMID:10889166]
217 Lok AS,Lai CL,Leung N,Yao GB,Cui ZY,Schiff ER,Dienstag JL,Heathcote EJ,Little NR,Griffiths DA,Gardner SD,Castiglia M.Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Gastroenterology 2003;125:1714-1722[PMID:14724824]
218 Leung NW,Lai CL,Chang TT,Guan R,Lee CM,Ng KY,Lim SG,Wu PC,Dent JC,Edmundson S,Condreay LD,Chien RN.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy.Hepatology 2001;33:1527-1532[PMID:11391543]
219 Marcellin P,Chang TT,Lim SG,Sievert W,Tong M,Arterburn S,Borroto-Esoda K,Frederick D,Rousseau F.Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.Hepatology 2008;48:750-758[PMID:18752330 DOI:10.1002/hep.22414]
220 Liaw YF,Gane E,Leung N,Zeuzem S,Wang Y,Lai CL,Heathcote EJ,Manns M,Bzowej N,Niu J,Han SH,Hwang SG,Cakaloglu Y,Tong MJ,Papatheodoridis G,Chen Y,Brown NA,Albanis E,Galil K,Naoumov NV.2-Year GLOBE trial results:telbivudine Is superior to lamivudine in patients with chronic hepatitis B.Gastroenterology 2009;136:486-495[PMID:19027013 DOI:10.1053/j.gastro.2008.10.026]
221 Chang TT,Lai CL,Kew Yoon S,Lee SS,Coelho HS,Carrilho FJ,Poordad F,Halota W,Horsmans Y,Tsai N,Zhang H,Tenney DJ,Tamez R,Iloeje U.Entecavir treatment for up to5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.Hepatology 2010;51:422-430[PMID:20049753DOI:10.1002/hep.23327]
222 Yuen MF,Seto WK,Fung J,Wong DK,Yuen JC,Lai CL.Three years of continuous entecavir therapy in treatmentnave chronic hepatitis B patients:VIRAL suppression,viral resistance,and clinical safety.Am J Gastroenterol 2011;106:1264-1271[PMID:21364549 DOI:10.1038/ajg.2011.45]
223 Kitrinos KM,Corsa A,Liu Y,Flaherty J,Snow-Lampart A,Marcellin P,Borroto-Esoda K,Miller MD.No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.Hepatology 2014;59 :434-442[PMID:23939953 DOI:10.1002/hep.26686]
224 Heathcote EJ,Marcellin P,Buti M,Gane E,De Man RA,Krastev Z,Germanidis G,Lee SS,Flisiak R,Kaita K,Manns M,Kotzev I,Tchernev K,Buggisch P,Weilert F,Kurdas OO,Shiffman ML,Trinh H,Gurel S,Snow-Lampart A,BorrotoEsoda K,Mondou E,Anderson J,Sorbel J,Rousseau F.Threeyear efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.Gastroenterology 2011;140:132 -143[PMID:20955704 DOI:10.1053/j.gastro.2010.10.011]
225 Marcellin P,Lau GK,Bonino F,Farci P,Hadziyannis S,Jin R,Lu ZM,Piratvisuth T,Germanidis G,Yurdaydin C,Diago M,Gurel S,Lai MY,Button P,Pluck N.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med2004;351:1206-1217[PMID:15371578]
226 Marcellin P,Avila C,Wursthorn K,Chuang WL,Lau GK,Peng CY.Telbivudine(LDT)plus peginterferon(PEGIFN)in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy(PN).J Hepatol 2010;52 :S6-S7[DOI:10.1016/S0168-8278(10)60015-3]
227 Gane E,Jia J,Han K,Tanwandee T,Chuang WL,Chuang WL.Neptune study:on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients.J Hepatol2011;54:S31
228 Sonneveld MJ,Rijckborst V,Boucher CA,Hansen BE,Janssen HL.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.Hepatology 2010;52:1251-1257[PMID:20830787 DOI:10.1002/hep.23844]
229 Piratvisuth T,Lau G,Chao YC,Jin R,Chutaputti A,Zhang QB,Tanwandee T,Button P,Popescu M.Sustained response to peginterferon alfa-2a(40 kD)with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.Hepatol Int 2008;2:102-110[PMID:19669285]
230 Gish RG,Chang TT,Lai CL,de Man R,Gadano A,Poordad F,Yang J,Brett-Smith H,Tamez R.Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-nave HBeAg-positive patients with chronic hepatitis B.J Viral Hepat 2010;17:16-22[PMID:19622117 DOI:10.1111/j.1365-2893.2009.01146.x]
231 Tassopoulos NC,Volpes R,Pastore G,Heathcote J,Buti M,Goldin RD,Hawley S,Barber J,Condreay L,Gray DF.Efficacy of lamivudine in patients with hepatitis B e antigennegative/hepatitis B virus DNA-positive(precore mutant)chronic hepatitis B.Lamivudine Precore Mutant Study Group.Hepatology 1999;29:889-896[PMID:10051494]
232 Rijckborst V,Hansen BE,Ferenci P,Brunetto MR,Tabak F,Cakaloglu Y,Lanza AG,Messina V,Iannacone C,Massetto B,Regep L,Colombo M,Janssen HL,Lampertico P.Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.J Hepatol 2012;56:1006-1011[PMID:22245886 DOI:10 .1016/j.jhep.2011.12.007]
233 Brunetto MR,Moriconi F,Bonino F,Lau GK,Farci P,Yurdaydin C,Piratvisuth T,Luo K,Wang Y,Hadziyannis S,Wolf E,McCloud P,Batrla R,Marcellin P.Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.Hepatology2009;49:1141-1150[PMID:19338056 DOI:10.1002/hep.22760]
234 Lai CL,Shouval D,Lok AS,Chang TT,Cheinquer H,Goodman Z,DeHertogh D,Wilber R,Zink RC,Cross A,Colonno R,Fernandes L.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N Engl J Med 2006;354 :1011-1020[PMID:16525138]
235 Lok AS,Hussain M,Cursano C,Margotti M,Gramenzi A,Grazi GL,Jovine E,Benardi M,Andreone P.Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.Hepatology 2000;32:1145-1153[PMID:11050068]
236 Hadziyannis SJ,Papatheodoridis GV,Dimou E,Laras A,Papaioannou C.Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Hepatology 2000;32:847-851[PMID:11003633]
237 Papatheodoridis GV,Dimou E,Laras A,Papadimitropoulos V,Hadziyannis SJ.Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Hepatology 2002;36:219-226[PMID:12085368]
238 Di Marco V,Marzano A,Lampertico P,Andreone P,Santantonio T,Almasio PL,Rizzetto M,CraxìA.Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.Hepatology 2004;40:883-891[PMID:15382125]
239 Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,Chang TT,Kitis G,Rizzetto M,Marcellin P,Lim SG,Goodman Z,Ma J,Brosgart CL,Borroto-Esoda K,Arterburn S,Chuck SL.Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.Gastroenterology 2006;131 :1743-1751[PMID:17087951]
240 Gane EJ,Wang Y,Liaw YF,Hou J,Thongsawat S,Wan M,Moon YM,Jia J,Chao YC,Niu J,Leung N,Samuel D,Hsu CW,Bao W,Lopez P,Avila C.Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.Liver Int 2011;31:676-684[PMID:21457439 DOI:10 .1111/j.14783231.2011.02490.x]
241 Lok AS,Trinh H,Carosi G,Akarca US,Gadano A,Habersetzer F,Sievert W,Wong D,Lovegren M,Cohen D,Llamoso C.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-nave patients with chronic hepatitis B.Gastroenterology 2012;143:619-628.e1[PMID:22643350]
242 Schiff E,Simsek H,Lee WM,Chao YC,Sette H,Janssen HL,Han SH,Goodman Z,Yang J,Brett-Smith H,Tamez R.Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.Am J Gastroenterol 2008;103:2776-2783[PMID:18721244 DOI:10 .1111/j.1572-0241.2008.02086.x]
243 Buti M,Hadziyannis S,Mathurin P,Urbanek P,Sherman M,Strasser S.Tenofovir disoproxil fumarate is highly active for treatment of chronic hepatitis B in subjects with cirrhosis.J Hepatol 2008;48:S33
244 Ha NB,Ha NB,Garcia RT,Trinh HN,Vu AA,Nguyen HA,Nguyen KK,Levitt BS,Nguyen MH.Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil.Hepatology 2009;50:727-734[PMID:19517525 DOI:10.1002/hep.23044]
245 Liaw YF,Sung JJ,Chow WC,Farrell G,Lee CZ,Yuen H,Tanwandee T,Tao QM,Shue K,Keene ON,Dixon JS,Gray DF,Sabbat J.Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med 2004;351:1521-1531[PMID:15470215]
246 Papatheodoridis GV,Dimou E,Dimakopoulos K,Manolakopoulos S,Rapti I,Kitis G,Tzourmakliotis D,Manesis E,Hadziyannis SJ.Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.Hepatology 2005;42:121-129[PMID:15962291]
247 Fontana RJ,Hann HW,Perrillo RP,Vierling JM,Wright T,Rakela J,Anschuetz G,Davis R,Gardner SD,Brown NA.Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.Gastroenterology 2002;123:719-727[PMID:12198698]
248 Papatheodoridis GV,Cholongitas E,Archimandritis AJ,Burroughs AK.Current management of hepatitis B virus infection before and after liver transplantation.Liver Int 2009;29:1294-1305[PMID:19619264 DOI:10.1111/j.14783231.2009.02085.x]
249 Grellier L,Mutimer D,Ahmed M,Brown D,Burroughs AK,Rolles K,McMaster P,Beranek P,Kennedy F,Kibbler H,McPhillips P,Elias E,Dusheiko G.Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.Lancet 1996;348:1212-1215[PMID:8898039]
250 Papatheodoridis GV,Lampertico P,Manolakopoulos S,Lok A.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review.J Hepatol 2010;53:348-356[PMID:20483498 DOI:10 .1016/j.jhep.2010.02.035]
251 Ferlay J,Shin HR,Bray F,Forman D,Mathers C,Parkin DM.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008.Int J Cancer 2010;127:2893-2917[PMID:21351269DOI:10.1002/ijc.25516]
252 El-Serag HB,Davila JA.Surveillance for hepatocellular carcinoma:in whom and howTherap Adv Gastroenterol 2011;4:5 -10[PMID:21317990 DOI:10.1177/1756283X10385964]
253 El-Serag HB,Siegel AB,Davila JA,Shaib YH,CaytonWoody M,McBride R,McGlynn KA.Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States:a population-based study.J Hepatol 2006;44:158-166[PMID:16290309]
254 Bruix J,Sherman M.Management of hepatocellular carcinoma.Hepatology 2005;42:1208-1236[PMID:16250051]
255 EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma.Eur J Cancer 2012;48:599-641[PMID:22424278 DOI:10.1016/j.ejca.2011.12.021]
256 Bruix J,Sherman M.American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update.Hepatology 2011;53:1020-1022[DOI:10.1002/hep.24199]
257 Omata M,Lesmana LA,Tateishi R,Chen PJ,Lin SM,Yoshida H,Kudo M,Lee JM,Choi BI,Poon RT,Shiina S,Cheng AL,Jia JD,Obi S,Han KH,Jafri W,Chow P,Lim SG,Chawla YK,Budihusodo U,Gani RA,Lesmana CR,Putranto TA,Liaw YF,Sarin SK.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Hepatol Int 2010;4:439-474[PMID:20827404 DOI:10 .1007/s12072-010-9165-7]
258 Zhang BH,Yang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol 2004;130:417-422[PMID:15042359]
259 Bolondi L.Screening tests for hepatocellular carcinoma.Hepatology 2003;37:1493;author reply 1493[PMID:12774028]
260 Kim CK,Lim JH,Lee WJ.Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver:accuracy of ultrasonography in transplant patients.J Ultrasound Med2001;20:99-104[PMID:11211142]
261 CraxìA,CammàC.Prevention of hepatocellular carcinoma.Clin Liver Dis 2005;9:329-46,viii[PMID:15831277]
262 Singal A,Volk ML,Waljee A,Salgia R,Higgins P,Rogers MA,Marrero JA.Meta-analysis:surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.Aliment Pharmacol Ther 2009;30:37-47[PMID:19392863 DOI:10.1111/j.1365-2036.2009.04014.x]
263 Sato T,Tateishi R,Yoshida H,Ohki T,Masuzaki R,Imamura J,Goto T,Kanai F,Obi S,Kato N,Shiina S,Kawabe T,Omata M.Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C.Hepatol Int 2009;3:544-550[PMID:19669240 DOI:10.1007/s12072-009-9145-y]
264 Tsukuma H,Hiyama T,Tanaka S,Nakao M,Yabuuchi T,Kitamura T,Nakanishi K,Fujimoto I,Inoue A,Yamazaki H.Risk factors for hepatocellular carcinoma among patients with chronic liver disease.N Engl J Med 1993;328:1797-1801[PMID:7684822]
265 McMahon BJ,Bulkow L,Harpster A,Snowball M,Lanier A,Sacco F,Dunaway E,Williams J.Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B:a 16-year population-based study.Hepatology 2000;32:842 -846[PMID:11003632]
266 Di Bisceglie AM,Sterling RK,Chung RT,Everhart JE,Dienstag JL,Bonkovsky HL,Wright EC,Everson GT,Lindsay KL,Lok AS,Lee WM,Morgan TR,Ghany MG,Gretch DR.Serum alpha-fetoprotein levels in patients with advanced hepatitis C:results from the HALT-C Trial.J Hepatol 2005;43:434 -441[PMID:16136646]
267 Yamashita T,Forgues M,Wang W,Kim JW,Ye Q,Jia H,Budhu A,Zanetti KA,Chen Y,Qin LX,Tang ZY,Wang XW.EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.Cancer Res2008;68:1451-1461[PMID:18316609 DOI:10.1158/0008-5472.CAN-07-6013]
268 Villanueva A,Minguez B,Forner A,Reig M,Llovet JM.Hepatocellular carcinoma:novel molecular approaches for diagnosis,prognosis,and therapy.Annu Rev Med2010;61:317-328[PMID:20059340 DOI:10.1146/annurev.med.080608.100623]
269 Szefler SJ.Leukotriene modifiers:what is their position in asthma therapyJ Allergy Clin Immunol 1998;102:170-172[PMID:9723656 DOI:10.1158/0008-5472.CAN-09-1089]
270 Trevisani F,D’Intino PE,Morselli-Labate AM,Mazzella G,Accogli E,Caraceni P,Domenicali M,De Notariis S,Roda E,Bernardi M.Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:influence of HBsAg and anti-HCV status.J Hepatol 2001;34:570 -575[PMID:11394657]
271 Chen JG,Parkin DM,Chen QG,Lu JH,Shen QJ,Zhang BC,Zhu YR.Screening for liver cancer:results of a randomised controlled trial in Qidong,China.J Med Screen 2003;10:204 -209[PMID:14738659]
272 El-Serag HB,Mason AC.Rising incidence of hepatocellular carcinoma in the United States.N Engl J Med 1999;340:745 -750[PMID:10072408]
273 Deuffic S,Buffat L,Poynard T,Valleron AJ.Modeling the hepatitis C virus epidemic in France.Hepatology 1999;29:1596-1601[PMID:10216148]
274 Barbara L,Benzi G,Gaiani S,Fusconi F,Zironi G,Siringo S,Rigamonti A,Barbara C,Grigioni W,Mazziotti A.Natural history of small untreated hepatocellular carcinoma in cirrhosis:a multivariate analysis of prognostic factors of tumor growth rate and patient survival.Hepatology 1992;16:132-137[PMID:1352268]
275 Ebara M,Ohto M,Shinagawa T,Sugiura N,Kimura K,Matsutani S,Morita M,Saisho H,Tsuchiya Y,Okuda K.Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis.A study in 22 patients.Gastroenterology 1986;90:289-298[PMID:2416627]
276 Sheu JC,Sung JL,Chen DS,Yang PM,Lai MY,Lee CS,Hsu HC,Chuang CN,Yang PC,Wang TH.Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.Gastroenterology 1985;89:259-266[PMID:2408960]
277 Santagostino E,Colombo M,Rivi M,Rumi MG,Rocino A,Linari S,Mannucci PM.A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus.Blood 2003;102:78-82[PMID:12649165]
278 Andersson KL,Salomon JA,Goldie SJ,Chung RT.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol 2008;6:1418-1424[PMID:18848905 DOI:10 .1016/j.cgh.2008.08.005]
279 Sangiovanni A,Del Ninno E,Fasani P,De Fazio C,Ronchi G,Romeo R,Morabito A,De Franchis R,Colombo M.Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.Gastroenterology 2004;126:1005-1014[PMID:15057740]
280 Trevisani F,De Notariis S,Rapaccini G,Farinati F,BenvegnùL,Zoli M,Grazi GL,Del PP,Di N,Bernardi M.Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma:effects on cancer stage and patient survival(Italian experience).Am J Gastroenterol 2002;97:734-744[PMID:11922571]
281 Santi V,Trevisani F,Gramenzi A,Grignaschi A,MiriciCappa F,Del Poggio P,Di Nolfo MA,BenvegnùL,Farinati F,Zoli M,Giannini EG,Borzio F,Caturelli E,Chiaramonte M,Bernardi M.Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.J Hepatol 2010;53:291-297[PMID:20483497 DOI:10.1016/j.jhep.2010.03.010]
282 Makuuchi M,Kokudo N,Arii S,Futagawa S,Kaneko S,Kawasaki S,Matsuyama Y,Okazaki M,Okita K,Omata M,Saida Y,Takayama T,Yamaoka Y.Development of evidencebased clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan.Hepatol Res 2008;38:37-51[PMID:18039202]
283 Nouso K,Tanaka H,Uematsu S,Shiraga K,Okamoto R,Onishi H,Nakamura S,Kobayashi Y,Araki Y,Aoki N,Shiratori Y.Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.J Gastroenterol Hepatol 2008;23:437-444[PMID:17683496]
284 Trinchet JC,Chaffaut C,Bourcier V,Degos F,Henrion J,Fontaine H,Roulot D,Mallat A,Hillaire S,Cales P,Ollivier I,Vinel JP,Mathurin P,Bronowicki JP,Vilgrain V,N’Kontchou G,Beaugrand M,Chevret S.Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis:a randomized trial comparing 3-and 6-month periodicities.Hepatology 2011;54:1987-1997[PMID:22144108 DOI:10.1002/hep.24545]
285 Fattovich G,Brollo L,Giustina G,Noventa F,Pontisso P,Alberti A,Realdi G,Ruol A.Natural history and prognostic factors for chronic hepatitis type B.Gut 1991;32:294-298[PMID:2013423]
286 Manno M,CammàC,Schepis F,Bassi F,Gelmini R,Giannini F,Miselli F,Grottola A,Ferretti I,Vecchi C,De Palma M,Villa E.Natural history of chronic HBV carriers in northern Italy:morbidity and mortality after 30 years.Gastroenterology2004;127:756-763[PMID:15362032]
287 Hsu YS,Chien RN,Yeh CT,Sheen IS,Chiou HY,Chu CM,Liaw YF.Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.Hepatology2002;35:1522-1527[PMID:12029639]
288 de Franchis R,Meucci G,Vecchi M,Tatarella M,Colombo M,Del Ninno E,Rumi MG,Donato MF,Ronchi G.The natural history of asymptomatic hepatitis B surface antigen carriers.Ann Intern Med 1993;118:191-194[PMID:8417636]
289 Sánchez-Tapias JM,Costa J,Mas A,Bruguera M,Rodés J.Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.Gastroenterology 2002;123:1848-1856[PMID:12454842]
290 Fattovich G.Natural history of hepatitis B.J Hepatol 2003;39Suppl 1:S50-S58[PMID:14708678]
291 Bellentani S,Tiribelli C,Saccoccio G,Sodde M,Fratti N,De Martin C,Cristianini G.Prevalence of chronic liver disease in the general population of northern Italy:the Dionysos Study.Hepatology 1994;20:1442-1449[PMID:7982643]
292 Evans AA,Chen G,Ross EA,Shen FM,Lin WY,London WT.Eight-year follow-up of the 90,000-person Haimen City cohort:I.Hepatocellular carcinoma mortality,risk factors,and gender differences.Cancer Epidemiol Biomarkers Prev 2002;11:369 -376[PMID:11927497]
293 Huo TI,Wu JC,Lee PC,Chau GY,Lui WY,Tsay SH,Ting LT,Chang FY,Lee SD.Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.Hepatology 1998;28:231-236[PMID:9657117]
294 Yuen MF,Wong DK,Sablon E,Tse E,Ng IO,Yuan HJ,Siu CW,Sander TJ,Bourne EJ,Hall JG,Condreay LD,Lai CL.HBsAg seroclearance in chronic hepatitis B in the Chinese:virological,histological,and clinical aspects.Hepatology 2004;39 :1694-1701[PMID:15185311]
295 Beasley RP,Hwang LY,Lin CC,Leu ML,Stevens CE,Szmuness W,Chen KP.Incidence of hepatitis B virus infections in preschool children in Taiwan.J Infect Dis 1982;146:198-204[PMID:7108271]
296 Villeneuve JP,Desrochers M,Infante-Rivard C,Willems B,Raymond G,Bourcier M,CtéJ,Richer G.A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal.Gastroenterology 1994;106:1000-1005[PMID:8143967]
297 Yu MW,Chang HC,Liaw YF,Lin SM,Lee SD,Liu CJ,Chen PJ,Hsiao TJ,Lee PH,Chen CJ.Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives.J Natl Cancer Inst 2000;92:1159-1164[PMID:10904089]
298 Kew MC,Marcus R,Geddes EW.Some characteristics of Mozambican Shangaans with primary hepatocellular cancer.S Afr Med J 1977;51:306-309[PMID:66757]
299 Kew MC,Macerollo P.Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks.Gastroenterology 1988;94:439-442[PMID:2446950]
300 Yuen MF,Tanaka Y,Fong DY,Fung J,Wong DK,Yuen JC,But DY,Chan AO,Wong BC,Mizokami M,Lai CL.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.J Hepatol 2009;50 :80-88[PMID:18977053 DOI:10.1016/j.jhep.2008.07.023]
301 Yang HI,Sherman M,Su J,Chen PJ,Liaw YF,Iloeje UH,Chen CJ.Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.J Clin Oncol 2010;28:2437-2444[PMID:20368541 DOI:10.1200/JCO.2009.27.4456]
302 Chen JD,Yang HI,Iloeje UH,You SL,Lu SN,Wang LY,Su J,Sun CA,Liaw YF,Chen CJ.Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liverrelated death.Gastroenterology 2010;138:1747-1754[PMID:20114048 DOI:10.1053/j.gastro.2010.01.042]
303 Wong GL,Chan HL,Mak CW,Lee SK,Ip ZM,Lam AT,Iu HW,Leung JM,Lai JW,Lo AO,Chan HY,Wong VW.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.Hepatology 2013;58:1537-1547[PMID:23389810 DOI:10.1002/hep.26301]
304 Sherman M.Does hepatitis B treatment reduce the incidence of hepatocellular carcinomaHepatology 2013;58:18-20[PMID:23401270 DOI:10.1002/hep.26317]
305 Tziomalos K.Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B.World J Hepatol 2010;2:91-93[PMID:21160979 DOI:10.4254/wjh.v2.i3.91]
306 Davila JA,Henderson L,Kramer JR,Kanwal F,Richardson PA,Duan Z,El-Serag HB.Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.Ann Intern Med 2011;154:85-93[PMID:21242365 DOI:10.7326/0003-4819-154-2-201101180-00006]
307 Davila JA,Morgan RO,Richardson PA,Du XL,McGlynn KA,El-Serag HB.Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.Hepatology 2010;52:132-141[PMID:20578139 DOI:10.1002/hep.23615]
308 Leykum LK,El-Serag HB,Cornell J,Papadopoulos KP.Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage,treatment received,and survival.Clin Gastroenterol Hepatol 2007;5:508-512[PMID:17382601]
309 Singal AG,Volk ML,Rakoski MO,Fu S,Su GL,McCurdy H,Marrero JA.Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma.J Clin Gastroenterol 2011;45:727-732[PMID:21602704DOI:10.1097/MCG.0b013e31820989d3]
310 Aberra FB,Essenmacher M,Fisher N,Volk ML.Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis.Dig Dis Sci 2013;58:1157-1160[PMID:23111632 DOI:10.1007/s10620-012-2461-4]